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ABSTRACT  
Diabetes mellitus places a substantial financial burden on the funder for treatment of this 
disease. This burden is compounded by the development of diabetes mellitus related 
complications. The cost of management of diabetes mellitus and its complications in South 
Africa in a tertiary level hospital is unknown. 
The objectives of this study were to: (1) develop a method to determine the cost of 
management of diabetes mellitus and its complications at Groote Schuur hospital, (2) 
quantify the direct medical costs associated with diabetes mellitus and its complications, and 
(3) develop models which could predict the cost of management of diabetes mellitus and its 
complications at Groote Schuur hospital.  
Patients were conveniently selected from Groote Schuur Hospital. Retrospective data were 
collected for 20 months from the two data sources available at Groote Schuur hospital, i.e., 
(1) electronic patient records and (2) patient folders.  Two methods of costing were 
developed, i.e., the combined method (using data from electronic database and patient 
folders) and the electronic method (using data from the electronic database only). The patient 
folders were used to complete any missing information from the electronic patient records. 
The combined method allowed better categorisation of costs compared to the electronic 
method. With the combined method the costs associated with diabetes mellitus (type I or type 
II) and diabetes mellitus complications could be categorized as the type of diabetes mellitus 
complications and the reasons for emergency room visits and hospitalisations were known.   
However, with the electronic method this categorisation could not be done. Both methods 
provided a total cost and cost per patient associated with diabetes mellitus and its 
complications.   
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Data from the combined method were arranged in the following main sub-groups for 
analysis: (1) type I diabetes mellitus, (2) type II diabetes mellitus, (3) diabetes mellitus, (4) 
diabetes mellitus with complications (5) diabetes mellitus complications only.   
The electronic method estimated a total cost which was 6.4% more than the combined 
method .The electronic method did not require the perusal of patient folders for additional 
information and hence it is a simplified method that could be used. When comparing the total 
costs and the average cost per patient for diabetes mellitus and diabetes mellitus with 
complications, there was no statistically significant difference between the combined method 
and the electronic method (p= 0.41). 
The average cost per patient per year for diabetes mellitus and diabetes mellitus with 
complications was R 1 231.54 and R 3 208.71, respectively. These results show that a patient 
with diabetes mellitus and its complications cost 2.6 times more to treat than a patient with 
diabetes mellitus only. The complications of diabetes mellitus contributed 60.7% to the total 
cost of diabetes mellitus and its complications. The cost of treating diabetes mellitus only and 
the cost of treating diabetes mellitus complications only were separated into 2 distinct 
categories. In this case, the cost of treating the complications of diabetes mellitus only was 2 
times more than treating diabetes mellitus only.  Type I diabetes mellitus cost R 3 011.32 and 
type II diabetes mellitus cost R 2 649.40 per patient per year. The treatment costs for type I 
diabetic patients was 13.7% more than that for type II diabetic patients. 
The decision tree model determined a cost which was 0.23% more than the actual cost 
obtained by the combined method. Hence, the decision tree method could be used to predict 
the total cost of diabetes mellitus and its complications.  
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Patients who attended Groote Schuur Hospital also received treatment for their diabetes at 
community health centres.   A method was developed which could predict the cost of 
management of diabetes mellitus at community health centres. This will allow the calculation 
of the total cost of diabetes mellitus and its complications from the perspective of the 
government. Four methods (i.e. combined, electronic, decision tree and prediction of costs at 
cost at community health centres) were developed in this study.   
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CHAPTER 1 
INTRODUCTION 
The International Diabetes Federation (IDF) has stated that diabetes mellitus is the most 
common non-communicable disease in the world (IDF. 2009). It was estimated that 4.5 % of 
the South African population was diabetic in 2010 and this prevalence is expected to increase 
in the next 20 years (Shaw et al. 2010). Diabetes mellitus (DM) is a chronic condition 
associated with a wide range of vascular complications (Winer et al. 2004). 
Diabetes mellitus places a substantial financial burden on the funder of treatment for this 
disease. This burden is compounded by the development of diabetes mellitus related 
complications which further increases the cost of treatment (Pelletier et al. 2008).    
The cost of managing diabetes mellitus and its complications has been documented in 
developed countries (Ramsey et al. 1999; Gandra et al. 2006; Clarke et al. 2008). In South 
Africa there is no published data on the costs of managing diabetes mellitus and its 
complications in a tertiary hospital. The increase in prevalence of diabetes mellitus will 
subsequently increase the need for relevant cost data. This study is therefore aimed at 
providing cost data on diabetes mellitus and its complications in a South African context.  
The South African health care environment is changing with the introduction of the National 
Health Insurance (NHI). Therefore, an even greater emphasis will be placed on funding and 
distribution of scarce monetary resources. It has become important that costs of common 
diseases such as diabetes mellitus are known. Knowledge of these costs may help funders i.e. 
government, when it comes to financial planning for health care.  
Costs for diabetes mellitus and its complications in South Africa are important, but of equal 
importance is the actual method of costing, using the data which is available. An important 
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consideration in costing is to evaluate the method which had been used to derive such costs. 
Such a method does not exist in South Africa for diabetes mellitus and its complications in a 
tertiary hospital. 
The public health care system is predominantly used in South Africa and therefore plays an 
important role. The National Treasury estimates that 84 % of South Africans utilise the public 
health care system (National Treasury. 2011). This shows the importance of developing cost 
data, and more importantly, developing methods which are created for the public sector 
taking into account the specific strengths and weaknesses of the data sources. 
This study was conducted in the public sector at Groote Schuur hospital (GSH). Costs in this 
sector are largely unknown and this presents a unique challenge to the government with 
regard to making health economic decisions. The study was conducted from the perspective 
of the funder of the treatment.  
This study had three primary objectives to: (1) develop a method to determine the cost of 
management of diabetes mellitus and its complications at Groote Schuur hospital, (2) 
quantify the direct medical costs associated with diabetes mellitus and its complications, and 
(3) develop models which could predict the cost of management of diabetes mellitus and its 
complications at Groote Schuur hospital.  
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In addition to the above mentioned, the study had the following specific objectives: 
a) To determine the best method for costing diabetes mellitus and its complications at 
Groote Schuur hospital. 
b) To determine the cost of treating a patient with diabetes mellitus only at Groote 
Schuur hospital. 
c) To determine the cost of treating a patient with diabetes mellitus and complication(s) 
(DMC) at Groote Schuur hospital. 
d) To determine the cost components which have a substantial impact on the cost of 
diabetes mellitus and its complications.  
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CHAPTER 2 
LITERATURE REVIEW 
This literature review will focus on the cost of diabetes mellitus and its complications and the 
use of economic models to predict costs of diabetes mellitus and its complications. In 
addition to this, the first part of the review will provide an overview of the prevalence and 
aetiology of diabetes mellitus and its complications, as this informs the development of the 
methods involved in predicting costs.  
The second part of this review will focus on economic models found in literature. These 
models will be assessed in terms of methods used. 
The third part of this literature review will focus on the research which has quantified the 
costs associated with diabetes mellitus and its complications. This review will evaluate the 
methods used in these studies and highlight the differences and similarities in the methods 
used and assess what possible conclusions could be developed as a result. Some of the 
common limitations of these studies will be highlighted and the relevance thereof evaluated.  
2.1 Diabetes mellitus 
Diabetes mellitus is now regarded as one of the most common non-communicable diseases in 
the world. It has become evident that developing countries, such as South Africa, will face 
the greatest burden in combating this disease (IDF. 2007). These developing countries face 
challenges such as reduced physical inactivity due to urbanisation and increasing prevalence 
of obesity, which are considered lifestyle related risk factors for diabetes mellitus (Shaw et al. 
2010).  
 
 
 
 
5 
 
Diabetes mellitus is a metabolic disorder which is characterised by resistance to the action of 
insulin, insufficient insulin secretion, or both (Gavin et al. 2003). Diabetes mellitus can be 
classified into two categories, type I diabetes mellitus and type II diabetes mellitus.  
Type I diabetes mellitus is caused by a deficiency of insulin in the body. Type II diabetes 
mellitus is caused by insulin resistance and a relative lack of insulin secretion, with 
progressively lower insulin secretion over time (Kuzuya et al. 2002). 
Type II diabetes mellitus is the most common form of diabetes mellitus with an estimated 
prevalence rate of 90 - 95%. Type I diabetes mellitus affects fewer diabetic patients with an 
estimated prevalence rate of 5 - 10% (Deshpande et al. 2008).  
2.2 Global prevalence of diabetes mellitus  
The global prevalence of diabetes mellitus is increasing rapidly. This increase is attributed to 
various factors such as population growth, aging, urbanisation and the increasing prevalence 
of obesity and physical inactivity (Shaw et al. 2010). The global prevalence rate for the year 
2010 was estimated at 6.4%. This translates into about 285 million people with diabetes 
mellitus worldwide (Shaw et al. 2010). The prevalence of diabetes is set to increase in the 
next 20 years as a result of the increasing incidence of diabetes. The current estimate for the 
year 2030 is 439 million people worldwide. This indicates an increase in prevalence of about 
50% over the next 20 years (Shaw et al. 2010). This shows the need for further research into 
diabetes mellitus and its impact on health care budgets.  
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2.2.1 Prevalence of diabetes mellitus in South Africa 
The prevalence of diabetes mellitus in South Africa was estimated at 4.5% in 2010 but, in 
line with global trends, this number is set to increase over the next 20 years. An estimated 
5.6% of the South African population will be diabetic in the year 2030 (Shaw et al. 2010).  
2.3 Types of diabetes mellitus complications 
Diabetes mellitus complications can be classified as either acute metabolic (short-term) 
complications or chronic (long-term) complications.  
The acute complications of diabetes mellitus include hypoglycemia, hyperglycemia, 
hyperosmolar diabetic ketoacidosis and diabetic ketoacidosis (Pepper et al. 2007). These 
complications develop over a short period of time and are reversible when treated 
appropriately. 
The chronic complications of diabetes mellitus are broadly classified into two distinct 
categories i.e., macrovascular and mircovascular complications (Deshpande et al. 2008). 
Macrovascular complications include cardiovascular disease (myocardial infarction, angina 
pectoris, heart failure, stroke and transient ischaemic attack) and peripheral vascular disease 
(foot ulcers, gangrene and amputations of the lower extremities) (Deshpande et al. 2008). 
Mircovascular complications include neuropathy, nephropathy and retinopathy (Deshpande et 
al. 2008). Table 1 indicates the economic implications of the various complications of 
diabetes mellitus. Treatment and management of these various complications will result an 
increase in the cost of treatment as indicated in Table 1 which was derived from a study by 
Williams et al. (2002).  
 
 
 
 
 
7 
 
Table 1: Chronic complications of diabetes mellitus and the economic implications  
System affected Disease  Economic implications 
Eyes Retinopathy 
Glaucoma 
Cataracts 
Blindness 
Drug therapy 
Surgery for cataract removal 
Photocoagulation therapy 
Hospitalisation 
Kidneys Renal failure 
Renal disease 
Drug therapy 
Dialysis 
Kidney transplant 
Hospitalisation 
Blood vessels Coronary artery disease 
Cerebral vascular disease 
Peripheral vascular disease 
Hypertension 
Drug therapy 
Surgery 
Hospitalisation 
 
Nerves Neuropathies  Drug therapy 
Surgery 
Hospitalisation 
Rehabilitation  
 
2.3.1 Prevalence of diabetes mellitus related complications 
Table 2 represents the prevalence rates of the most common diabetes mellitus complications 
according to a survey conducted in the United States of America between 1999 and 2004 by 
the National Health and Nutrition Examination Survey (Deshpande et al. 2008).  
Table 2: Prevalence of common diabetes mellitus related complications 
Diabetes mellitus related complication Prevalence rate 
Chronic kidney disease (Nephropathy) 27.8% 
Peripheral vascular disease  22.9% 
Eye complications (Retinopathy) 18.9% 
Heart attack 9.8% 
Chest pain 9.5% 
Coronary heart disease 9.1% 
Congestive heart failure 7.9% 
Stroke 6.6% 
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Cardiovascular disease
1
 42.9% 
1 
Cardiovascular diseases grouped as a single disease using prevalence rates from the study.  
Although nephropathy as a single disease has the highest prevalence, the cardiovascular 
complications when grouped as a single disease have the highest prevalence rate (Deshpande 
et al. 2008). 
Although these chronic complications can occur in any person, they have shown to occur 
more frequently in diabetic patients. An estimated 65% of all deaths in people with diabetes 
mellitus have been caused by cardiovascular disease (Leibson et al. 2005; Booth et al., 2006). 
Lower extremity amputations, due to peripheral vascular disease, are at least 10 to 20 times 
more likely to occur in patients with diabetes mellitus (Sugarman et al. 1998). 
Cardiovascular disease, nephropathy and diabetic retinopathy are the most common diabetes 
mellitus related complications in diabetic patients.  
2.4 Economic models  
Various studies have shown the value of economic models in costing diabetes mellitus and its 
complications (Coyle et al. 2002; Clarke et al. 2008; Zhou et al. 2005).  
Many of the models currently available mainly focus on type II diabetes mellitus. These 
models have similar characteristics in that they follow Markov based microsimulation and 
utilises data from various epidemiological studies and databases. However, these models do 
vary significantly in the types and number of diabetes mellitus complications covered by the 
models (Coyle et al. 2002). 
There are a number of computer simulated models that have been developed, these, however, 
have not been discussed here as they are not relevant to this study (Zhou et al. 2005). 
 
 
 
 
9 
 
A study by O’Brien and colleagues (2003) used a model to determine the costs of type II 
diabetes mellitus and its complications in Canada. This model used probabilities from 
published sources to determine occurrence of complications, then unit costs were applied to 
the likely course of treatment for each complication. Various cost sources were used in that 
study; namely, Alberta Ambulatory Care Costing project, Ontario Care Cost project, 
Canadian Diabetes Association and the Canadian clinical practice guidelines.  A similar 
method of costing was used in other studies in the United States of America and Canada 
(O’Brien et al. 2001; Eastman et al. 1997). Clarke and colleagues (2008), used data from an 
Australian managed health care database to estimate the costs of diabetes mellitus and its 
complications. Probabilities for certain complications of diabetes mellitus were determined 
and unit costs were applied for the likely treatment route to be taken for these complications. 
Cost information was derived from insurance claims from the managed health care 
organisation. 
Models have been found to allow decision makers to use short-term clinical data to forecast 
long-term costs and benefits. Many of the models discussed here are based on similar 
principles of construction and organisation. These models used published epidemiological 
data to obtain probabilities for occurrence of certain events. These models do, however, differ 
in the type and number of complications assessed and in the complexity of the model 
(O’Brien et al. 2001; 2003; Clarke et al. 2008). 
2.5 Cost of diabetes mellitus and its complications 
The third part of the literature review will evaluate the studies which have quantified the 
costs associated with diabetes mellitus and its complications. The various methods used in 
these studies and the economic impact thereof will be assessed. 
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2.5.1 Methods used in cost studies 
2.5.1.1 Data sources (Electronic database versus Patient folders) 
There are two main data sources used in cost studies, viz. patient folders and electronic 
databases containing claims data from managed health care organisations. Data from 
developed countries were extracted mainly from electronic databases. There were few studies 
described in the literature which used patient folders as the primary data source. Table 3 
summarises the data sources in the literature. 
Table 3: Data sources used in literature 
Author, date Electronic vs 
Patient 
folders 
Time period 
studied 
Study type Number of 
patients in 
study 
Country 
Pelletier et al. 
2008 
Electronic  January 2003 to  
December 2004 
Retrospective 
cohort analysis 
44 021 United States of 
America 
Riewpaiboon et 
al. 2007 
Paper-based  October 2000 to  
September 2001 
Retrospective 
cohort analysis 
186 Thailand 
Morsanutto et al. 
2006 
Paper-based 
and electronic  
January 2001 to  
August 2002 
Retrospective 
longitudinal 
analysis 
299 Italy 
Gandra et al. 2006 Electronic  January 2003 to  
December 2003 
Retrospective 
cohort analysis 
9 059 United States of 
America 
Ramsey et al. 
1999 
Electronic  January 1992 to 
December 1995 
Retrospective 
cohort analysis 
8 905  United States of 
America 
Clarke et al. 2006 Electronic  July1995 
to 
June 1999 
Retrospective 
cohort analysis 
20 538 Australia 
Brandle et al. 
2003 
Electronic  April 2000 
to 
February 2001  
Retrospective 
cohort analysis 
1 364 United States of 
America 
Pelletier et al. 
2009 
Electronic  January 2002 to 
December 2005 
Retrospective 
cohort analysis 
15 326 United States of 
America 
Stock et al. 2005 Electronic  January 1999 
to 
December 1999 
Retrospective 
cohort analysis 
158 629 Germany 
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Clarke et al. 2008 Electronic  January 1990 
to 
December 1999 
Retrospective 
cohort analysis 
70 340 Australia 
Massi-Benedetti. 
2002 
Electronic   Bottom-up 
prevalence 
based study 
>  7 000 Europe 
  
2.5.2 Diabetes mellitus related complications in cost studies 
There have been various complications of diabetes mellitus included in cost studies. The 
majority of these studies focussed on the chronic complications of diabetes mellitus, while 
only Pelletier et al. (2008) and Riewpaiboon et al. (2007) included short-term acute 
metabolic complications. 
The United Kingdom Prospective Diabetes Study conducted in 2003 (Clarke et al.2003) lists 
hypertension and hyperlipidaemia as risk factors for the development of diabetes mellitus 
complications. Some studies in the cost literature have recorded conditions such as 
hypertension and hyperlipidaemia as complications of diabetes mellitus (Riewpaiboon et al. 
2007; Ramsey et al. 1999).  
Cardiovascular complications were commonly investigated as single disease states. Similarly, 
the consequences of peripheral vascular disease such as gangrene, diabetic foot and 
amputations were reported as separate diseases states including peripheral vascular disease. 
As indicated in Table 3, the number of complications studied varied and not all the 
complications of diabetes mellitus were included. Stroke was only mentioned in 3 of the 9 
studies presented in Table 3. 
These resulting inconsistencies in the grouping or definitions of complications within the cost 
studies can cause difficulty in interpretation of the cost of diabetes mellitus and its 
complications. 
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Table 4: Most common diabetes mellitus complications included in cost literature 
Reference  Prevalence of diabetes mellitus complications  Number of 
patients 
included in 
study 
Pelletier et al. 2008 Retinopathy 
Neuropathy 
Heart Failure 
Angina Pectoris 
Renal disease 
Peripheral vascular disease 
Foot ulcer 
Myocardial infarction 
Ischaemic stroke 
Blindness 
Hypoglycaemic event 
Ketoacidosis 
28.7% 
25.4% 
14% 
12% 
11% 
10.6% 
8.5% 
7.2% 
5% 
0.9% 
0.2% 
0.2% 
44 021 
Riewpaiboon et al. 
2007 
Hypertension 
Neuropathy 
Hyperlipidaemia 
Diabetic foot 
Nephropathy 
Ischaemic heart disease 
Cerebrovascular accident 
Hyperglycaemia 
Hypoglycaemia 
Retinopathy 
Gangrene 
 
 
41.1% 
35.5% 
16.1% 
13.4% 
7% 
4.3% 
3.8% 
2.7% 
1.1% 
0.5% 
0.5% 
 
186 
Morsanutto et al. 2006 Retinopathy  
Nephropathy  
Cardiopathy  
Other  
27.4% 
20.5% 
19.7%           
32.5%      
299 
Gandra et al. 2006 Retinopathy  
Nephropathy 
Neuropathy 
12.6% 
5.9% 
5.5%                          
9 059 
Ramsey et al. 1999 Eye disease 
Hypertension 
Myocardial infarction 
Stroke 
Foot ulcer 
End-stage renal disease 
44.3% 
26.2% 
9.3% 
8.7% 
7.9% 
5.9% 
8 905 
Clarke et al. 2005 Vascular disease 
Ischaemic heart disease 
Cerebrovascular disease 
Acute Myocardial infarction 
Renal disease  
Amputations 
5.1%    
3.9%       
1.8%    
1.5%   
1.1%     
0.5%          
20 538 
 
 
 
 
13 
 
Brandle et al. 2003 Neuropathy 
Peripheral vascular disease  
Myocardial infarction 
Cerebrovascular disease 
Nonproliferative retinopathy 
Angina 
Proliferative retinopathy 
End-stage renal disease 
40%     
39%      
27%       
15%   
12%    
4%     
3%    
0.4%       
1 364 
Pelletier et al. 2009 Peripheral neuropathy 
Diabetic retinopathy 
Nephropathy 
Other diabetic complications 
Dialysis  
60.5%   
28.1%      
18.9%      
1.4%   
1%                                                              
15 326 
Clarke et al. 2008 Fatal myocardial infarction 
Non-fatal myocardial infarction  
Fatal stroke  
Non-fatal stroke   
Ischaemic heart disease        
Heart failure  
Renal failure  
Blindness  
Foot ulcer  
Amputation 
Cost 
estimates 
provided. 
No patient 
level data 
70 340 
 
2.5.3 Cost components 
The direct medical costs associated with the treatment of diabetes mellitus and its 
complications consist of various components. Campbell et al. (1997) described two types of 
cost components which included ambulatory and hospital care. Ambulatory care comprised 
of doctor consults, clinic visits, drug therapy and self-monitoring therapy. These costs 
occurred in an outpatient setting. The sub-components of hospital care were not provided. 
The most widely used cost components in cost analysis were medicines, laboratory/diagnostic 
tests, doctor/specialist consultations, emergency room visits and hospitalisations (Pelletier et 
al. 2008; Riewpaiboon et al. 2007; Morsanutto et al. 2006; Clarke et al. 2005).  
An evaluation of the literature revealed that while medicine cost is commonly reported, some 
researchers have further categorised and identified the types of medicines which were 
included in the cost analysis. For example, Pelletier et al. (2008) further reported medicines 
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in four categories based on the type of medicines i.e., insulin, oral hypoglycaemic agents, 
ACE inhibitors and statins/antihyperlipidaemics. Riewpaiboon et al. (2007) also reported 
medicines according to the type of medicine but included vitamin B1-4, vitamin B12 and 
vitamin B complex in the cost of medicines. Vitamins are not commonly considered as 
medicines to treat diabetes mellitus or its complications, therefore this could result in an 
overestimation of medicine cost. O’Brien et al. (2003) categorised and clearly identified the 
medicines used in the treatment of diabetes mellitus and its complications. Riewpaiboon et al 
(2007) included another component to the cost of medicine i.e., the cost of dispensing. 
Hospitalisation can consist of various components such as bed stay, laboratory tests, 
medicines, doctor consultations, nursing care and surgery. Numerous studies reported 
hospitalisation as a component cost (Brandle et al. 2003; Ramsey et al. 1999; Gandra et al. 
2006). These studies provide no further categorisation into the various components of 
hospitalisation which were included in the studies. The cost of hospitalisation may not reflect 
the true cost as some components such as laboratory tests conducted, nursing time and other 
general ward items used during the hospitalisation may not have been taken into account. 
Riewpaiboon et al. (2007) reported surgery and hospitalisation as two separate costs. No 
further explanation was provided as to whether the hospitalisation was due to surgery or a 
separate unrelated event.  In an Australian study, Clarke et al. (2005) reported hospital costs 
which included day surgery.  
The cost components have an immense effect on the cost results obtained. Detailed reporting 
of the cost components included in the cost analysis adds greater validity to the study and 
subsequent conclusions derived from the study. 
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2.5.4 Cost of treating diabetes mellitus and diabetes mellitus complications 
The treatment of diabetes mellitus and its complications has been shown to be costly and a 
large proportion of health care budgets were used on these treatments. The International 
Diabetes Federation (IDF) estimated that the global health care expenditure for diabetes 
mellitus and its complications was 11.6% of the total health care expenditure in 2010.  
During the same period, 7% of the total health care expenditure for both Africa and South 
Africa (individually) was spent on diabetes mellitus and its complications (IDF. 2009).  
Numerous studies conducted on the treatment of diabetes mellitus and its complications 
showed that the diabetes related complications contribute the largest proportion of the total 
costs of diabetes mellitus treatment (Norlund et al. 2001; O’Brien et al. 2003; Simpson et al. 
2003; Williams et al. 2002).  
According to the American Diabetes Association (ADA) the cost of treating diabetes mellitus 
and its complications in the United States in 2007 was 174 billion US dollars and of this 58 
billion US dollars was spent on the treatment of diabetes related complications (ADA. 2008). 
The complications of diabetes mellitus therefore contribute 33.3% of the total cost of treating 
diabetes mellitus and its complications. 
Diabetes mellitus complications may require hospitalisation for management. These 
hospitalisations have been documented as the largest cost drivers in the treatment of diabetes 
mellitus complications. Researchers found that hospitalisations contribute as much as 50% of 
the total cost of treatment. Dawson et al. (2000) found that 50% of the total cost of treatment 
was due to hospital care, while medication and doctor consultations accounted for 31% and 
19%, respectively, of the total cost. Jonsson B. (2002) reported that hospitalisation accounted 
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for 55 % of the total cost on average but this figure ranged between 30% and 65% of the total 
cost.  
Williams et al. (2002) reported that the complications of diabetes mellitus increased 
hospitalisation cost by 450% when compared to diabetic patients without complications. 
Patients with a macrovascular complication had a 7-fold increase in hospital costs compared 
to patients with no diabetes mellitus complications (Gandra et al. 2006).  
An Italian study compared the distribution of annual treatment costs among patients with and 
without diabetes mellitus complications. These results indicated that for patients with a 
complication(s), 28% of the treatment cost was due to hospitalisations in comparison to 1% 
for patients without a complication (Morsanutto et al. 2006).  
The CODE-2 study reported an increase of 70% in the treatment costs for patients with a 
microvascular complication compared to patients without any complications. This study also 
reported that patients with a macrovascular complication had double the treatment costs 
compared to patients with no complications (Massi-Benedetti, M. 2002).  
The number of diabetes mellitus complications will also have an impact on the costs of 
diabetes treatment. This was demonstrated in the study by Currie et al. (2005) who reported 
that patients with 3 complications had a 6-fold increase in annual treatment costs compared to 
patients with a single complication. Morsanutto et al. (2006) reported that patients who had 
two or more diabetes mellitus complications had a 3-fold increase in costs versus patients 
with no complication(s). Hospitalisation was the greatest contributor to the total cost, 
increasing from 1% for patients with no complication to 40% for patients with two or more 
complications.   
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A cost of illness study found that cardiac, coronary disease and stroke were the most costly 
diabetes mellitus complications among type 2 diabetic patients (Gonzalez et al. 2009). 
Cardiovascular disease was found to be the most common complication and also the most 
costly diabetes mellitus complication by some researchers (Nichols and Brown. 2002; 
Morsanutto et al. 2006; Simpson et al. 2003). Pelletier et al. (2008) reported heart failure, 
myocardial infarction and renal disease as the most costly diabetes mellitus complications.  
Similarly, results obtained in Mexico among type 2 diabetics indicated that chronic kidney 
failure was the most costly to treat, while cardiovascular disease resulted in significant 
resource use which increased treatment costs (De los Ángeles Rodríguez Bolaños et al. 
2010).  
In summary, a review of various literature indicated that macrovascular complications, in 
particular cardiovascular complications, were the most costly diabetes mellitus complications 
in addition to occurring frequently amongst the diabetic populations studied. 
2.5.5 Cost studies in South Africa 
Limited data is available in South Africa regarding the costs for treating diabetes mellitus and 
its complications. One published study reported the costs of treating acute metabolic diabetes 
mellitus complications in a secondary level hospital (Pepper et al. 2007). This study was 
conducted over a 2 month period and costs were calculated using the public sector pricing. 
Data were collected prospectively and patient folders were used as the primary source of 
data. A average cost of R 5 309.49 per admission was reported (2005 costs), the largest 
contributor to this cost was nursing care. The average hospitalisation period reported was 4 
days (Pepper et al. 2007). The results of this study showed that acute prevenTable 
 
 
 
 
18 
 
complications of diabetes mellitus placed a huge financial burden on the funder of the 
treatment in South Africa. 
A review of literature revealed that no studies have been published in South Africa on the 
total cost of diabetes mellitus and its complications in any particular setting in South Africa. 
2.6 Limitations of cost studies 
2.6.1 Data sources  
Various data sources were used in the studies to quantify the costs of treating diabetes 
mellitus and its complications. The accuracy of the data sources directly affect the cost data 
which are collected and reported. If the data which were collected do not represent the entire 
diabetic population of the specific region and the results cannot be generalised to a wider 
population. The accuracy of the database is highly dependent on the data capturers and the 
coding process (Pelletier et al. 2005; Morsanutto et al. 2006; Gandra et al. 2006).  
The full cost of diabetes mellitus treatment cannot be reported when using electronic claims 
from administrative health insurance data as the costs reported do not include patient co-
payments and any other out of pocket payments (Clarke et al. 2008; Stock et al. 2005; 
Pelletier et al. 2009).  
Data sources such as patient folders have several limitations. The data may be incomplete, 
some information may be missing or medical records may not be accurately completed and 
kept up to date (Riewpaiboon et al. 2007).  
Data sources and their limitations have an effect on the results reported. These costs will in 
most cases be underestimated due to the limitations discussed above (Akobundu et al. 2006). 
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2.6.2 Cost perspective 
An important consideration when assessing the cost studies is the perspective of the study as 
this can affect the way in which the cost results are interpreted. There are 3 main perspectives 
from which these studies were conducted i.e., (1) the patient, (2) the provider of health care 
and (3) the funder of the treatment (Akobundu et al. 2006). The perspectives of the funder of 
the treatment and the provider of health care are similar in that only direct medical costs are 
assessed. The patient perspective will assess both the direct and indirect medical costs 
(Kishore et al. 2009).   
These differences in cost studies show that there is no standard method for estimating the 
costs of treating diabetes mellitus and its complications. 
2.7 General comment on literature review 
Diabetes mellitus is a complex chronic disorder with both short-term (acute) and long-term 
(chronic) complications which are costly to treat and manage. Studies (Pelletier et al. 2005; 
Morsanutto et al. 2006; Clarke et al. 2008; Chatterjee et al. 2011) have repeatedly found a 
large economic burden associated with the treatment of diabetes mellitus and its 
complications. Economic models predict costs and therefore aid the decision making process.   
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CHAPTER 3 
PLAN OF WORK 
The purpose of this chapter is to provide an overview of the methods which were used in the 
study. The details of these methods are described in chapter 4. 
3.1 Study objectives 
The overall objectives of this study were to (1) develop a method to determine the cost of 
management of diabetes mellitus and its complications at Groote Schuur hospital, (2) 
quantify the direct medical costs associated with the management of diabetes mellitus and its 
complications and (3) develop a model which could predict the cost of management of 
diabetes mellitus and its complications at Groote Schuur hospital. 
3.2  Overview of the methods used 
Patients who attended the adult diabetic clinic at Groote Schuur hospital were indentified 
from the electronic database for possible inclusion in the study. The inclusion and exclusion 
criteria were applied. Patient validation criteria were applied to ascertain a diagnosis of 
diabetes mellitus and the complications of diabetes mellitus. There were two data sources 
available at Groote Schuur hospital i.e., (1) electronic patient records and (2) patient folders. 
 3.2.1 Cost method 
Two cost methods were developed in this study: 
(1) The combined method 
(2) The electronic method 
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3.2.1.1  Combined method 
The combined method utilised data from the electronic patient records and patient folders. 
The patient folders were used to complete any missing information from the electronic 
patient records. The patient folders provided additional clinical information which was used 
to categorise costs into (1) costs due to diabetes mellitus and (2) costs due to the 
complications of diabetes mellitus. The reasons for hospitalisation and emergency room visits 
were obtained from the patient folders. 
3.2.1.2  Electronic method 
The electronic method utilised data from the electronic patient records only. 
Data which was obtained from the electronic database was used. Patient diagnoses were not 
available in this database. Patients’ medicine history was used to categorise patients into (1) 
insulin dependent diabetes mellitus and (2) non-insulin dependent diabetes mellitus. It was 
assumed that if a patient had specific laboratory tests conducted or visited certain clinics at 
Groote Schuur hospital, it would reflect the presence of a complication of diabetes mellitus.  
Each of these methods, i.e., the combined and electronic methods, provided a total cost and 
cost per patient.  
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3.2.2  Source of costs 
In this study costs were obtained from the following sources: 
a) UPFS Provincial Gazette for Western Cape No. 6862, 25 March 2011. This included 
costs for doctor consultations, dispensing fee, electrocardiogram and radiological 
procedures, emergency room visits, hospitalisations and surgeries. 
b) Pharmacy department at Groote Schuur hospital provided the cost for the medicines 
and other pharmacy supplies. 
c) National Health Laboratory Services provided costs for the laboratory tests. 
3.2.3  Categorisation of costs 
In this study costs were broadly categorised into (1) costs due to diabetes mellitus and (2) 
costs due to the complications of diabetes mellitus. The categorisation of these costs was 
based on the clinical data of each patient. 
3.3  Model development 
The primary model developed was a predictive cost model for diabetic patients at Groote 
Schuur hospital. This model was based on the decision tree algorithm and utilised 
probabilities of the occurrence of type I or type II diabetes and whether or not complications 
would occur. Cost estimates for a period of one year were obtained for the following 
categories: 
a) Type I diabetes mellitus without complications 
b) Type I diabetes mellitus with complications 
c) Type II diabetes mellitus without complications 
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d) Type II diabetes mellitus with complications 
Statistical analyses were applied to the results obtained to determine if the differences in the 
following total and average costs were statistically significant: 
a) Combined method versus electronic method 
b) Diabetes mellitus versus diabetes mellitus with complications 
c) Type I versus type II diabetes mellitus 
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CHAPTER 4 
METHODS 
This chapter provides a detailed description of the methods used in this study. This research 
method consisted of two parts, (1) development of a cost method and (2) development of a 
predictive cost model for the diabetic population of Groote Schuur hospital. 
4.1  Selection of the study site 
Many of the complications of diabetes mellitus require hospitalisation and specialised care 
for treatment. Hence, Groote Schuur hospital (GSH) was conveniently selected as the study 
site. This tertiary level hospital is located in the Cape Metropole area and is part of the 
Associated Academic Hospitals' group. It is a government funded teaching hospital and many 
of the doctors employed at Groote Schuur hospital are specialists involved in training of 
medical professionals and research. This hospital was selected on the basis that it is a referral 
hospital for the treatment and care of patients with complications of diabetes mellitus.  
4.2  Patient extraction from electronic database of patient records 
Patients with diabetes mellitus and its complications were extracted from the electronic 
database of Medical Informatics at Groote Schuur hospital. The method of extracting patients 
from the electronic database was developed in consultation with Ms. Wendy Bryant 
(Director, Medical Informatics, Groote Schuur hospital) and Professor Naomi Levitt (Head 
Diabetic Medicine and Endocrinology, University of Cape Town and Groote Schuur 
hospital). The patients who attended the adult diabetic clinic at Groote Schuur hospital were 
identified for possible inclusion in the study. This method of extracting these patients was 
preferred over the conventional method of extracting patients by using International 
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Statistical Classification of Diseases and Related Health Problems (ICD-10) codes specific to 
diabetes mellitus and its complications.  
The recording of ICD-10 codes in the electronic database was not considered to be accurate 
and it was possible that not all the diabetic patients would have been included if this method 
had been used.  
4.3  Patient Selection 
4.3.1  Inclusion criteria  
Patients were included in the study based on the following criteria: 
a) had diabetes mellitus; 
b) had diabetes mellitus related complications; and 
c) over the age of 18 years. 
4.3.2  Exclusion criteria 
Patients were excluded from the study based on the following criteria: 
a) had a cancer co-morbidity as these patients have shown to incur high medical costs 
(Gandra et al. 2006); and 
b) had diabetes mellitus as a result of  pregnancy, drug-or-chemical induced diabetes or 
diabetes as a result of an underlying condition (e.g. pancreatitis). 
4.3.3  Sampling  
A total of 1094 patient records were extracted from Groote Schuur hospital based on the 
extraction method. A convenience sampling method was applied. Patient folders were 
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requested from Medical Records at Groote Schuur hospital until a sample of 100 patients was 
obtained based on the inclusion criteria.   
4.4  Study design 
This was a retrospective cohort analysis. 
4.5  Study period 
Data were collected from 1
st
 April 2009 until 31
st
 December 2010.  
4.6  Data collection 
The researcher was trained by Professor Levitt on how to extract and obtain relevant 
information from the patient folders.    
Information on every patient was extracted from two sources: 
a) electronic patient records 
b) patient folders 
Patient hospital identification numbers were obtained from the electronic database. A patient 
list was then compiled and presented to the Medical Records department at Groote Schuur 
hospital for retrieval of the patient folders.  
The researcher extracted from each patient folder the information necessary for the cost 
analysis for the study period of interest. It took on average 45 minutes to one hour to 
complete the collection of data from each patient folder.  
The main purpose of the manual extraction of information from the patient folder was to 
complete any missing patient data that had not been included in the electronic patient records. 
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The information in the patient folder was used to verify the information in the electronic 
database of patient records.  
4.7  Patient validation 
The following criteria were used to validate the diagnosis of diabetes mellitus for each 
patient. If the patient met any one of the following criteria, the diagnosis of diabetes mellitus 
was confirmed.  
a) a diagnosis of diabetes mellitus recorded in the patient folder; 
b) a medication history which included either insulin or an oral hypoglycaemic agent or 
both; and 
c) a record of a laboratory test which included either a glucose or glycated haemoglobin 
test or both. 
The electronic patient record did not have information regarding the diagnosis of diabetes 
mellitus complications. Hence, the patient folders were used to complete missing information 
or to validate the diagnosis of a complication of diabetes mellitus together with the 
information in the electronic database. If conflicting information was present between the 
folder and electronic database, then the information obtained in the folder was accepted as the 
most accurate, as there probably would be no capture error from this source. 
4.8.1  Electronic database of patient medical records 
This was used as the primary source of the following patient information: 
a) general patient information which included the first name, surname, hospital 
identification number and date of birth; 
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b) history of outpatient doctor consultations which included the date of consultation, 
clinic/department visited and reason for consultation;  
c) history of patient medication received which included the name of medicine, pack 
size, quantity, date and total cost per medicine dispensed for the study period; 
d) history of laboratory tests conducted which included the name, date and cost of the 
laboratory test;  
e) history of radiological and electrocardiography procedures performed which included 
the type and date of procedure; 
f) history of emergency room visits which included the date and reason for visit;  
g) history of inpatient hospitalisations which included the date of admission and 
discharge, length of stay and reason for hospitalisation; and  
h) history of surgeries conducted which included the date and type of surgery and 
duration of anaesthesia and surgery. 
The information in the main database was compiled from various sources within the hospital. 
The accuracy of the information was subject to the accuracy with which the personnel 
captured the information into the database from the primary source. Data were entered at 
various points throughout the hospital into the central database of the Medical Informatics 
department. 
The information on laboratory tests was compiled by the Medical Informatics department 
directly from the National Health Laboratory Services (NHLS). The medicine information 
was compiled from the pharmacy dispensing programme.    
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4.8.2  Patient folders 
These were used as the secondary data source of patient information. The following 
information was obtained from this data source: 
a) general patient information which included the name, surname, gender, date of birth, 
contact numbers and address. This information was used for identification purposes 
only and was not disclosed at any time during the study or within the thesis; 
b) clinical information relating to the patient which included co-morbidities and 
diagnosis of patient, past and current medical history. A clinic consultation form was 
used by the doctor when consulting with a diabetic patient (Annexure 1). This form 
was designed by Groote Schuur hospital; 
c) information on medication, derived from the prescription charts which were issued by 
doctors at Groote Schuur hospital; 
d) consultations with doctors and other health care providers at Groote Schuur hospital, 
emergency room visits, inpatient hospitalisations and surgeries; and 
e) printed reports of laboratory tests, electrocardiography (ECG) tests and radiological 
procedures. 
The accuracy of the information in the patient folders was subject to the accuracy of the 
healthcare staff recording such information. There were variations in the recording of 
information between various health care staff. For example, in a particular instance the 
diagnosis of the type of diabetes mellitus was recorded differently throughout the folder. 
Patient co-morbid conditions were also not always documented.  
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4.9   Source of costs 
The following cost sources were used in the study: 
a) the laboratory test costs were obtained from the Medical Informatics department at 
Groote Schuur hospital. These cost data were extracted from the National Health 
Laboratory Service (NHLS). This reflected the cost to Groote Schuur hospital for the 
laboratory test. 
b)  the cost for medicines, diagnostic tests (e.g. blood glucose test strips), syringes and 
needles were obtained from the pharmacy department. The cost reflected the 
acquisition cost to Groote Schuur hospital. 
c) the costs for the following components were obtained from the Unified Patient Fee 
Schedule (UPFS), Provincial Gazette for Western Cape, No. 6862, 25 March 2011: 
a. outpatient doctor consultation cost which consisted of two costs, viz. the 
facility fee and specialist fee; 
b. medicine dispensing cost which consisted of a facility fee; 
c. radiological and electrocardiography procedure costs which consisted of a 
facility fee and specialist fee; 
d. emergency room visit cost which consisted of a facility fee and specialist fee; 
e. inpatient overnight hospital cost which consisted of a facility fee and specialist 
fee; and 
f. surgery cost which consisted of two costs, viz. anaesthetic fee and theatre fee. 
The theatre fee consisted of two costs, a facility fee and specialist fee. 
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The UPFS is the price that the government charges private patients who attend government 
facilities. 
Table 5 indicates the various components which are included in the facility fee.  
Table 5  UPFS facility fee components  
Facility fee Components 
Outpatient consultation Cost of facility only 
Emergency room visit Nursing time 
Medicines used 
Hospitalisation Bed stay cost 
Nursing time 
Medicines used 
General ward items used 
Surgery Nursing time  
General surgery items used 
  
Table 6 indicates the unit cost which was obtained from the UPFS fee schedule for the 
various cost components.  
Table 6 Unit cost of UPFS fees  
Component Unit cost (Rands) 
Specialist consultation R 241.00 
Dispensing fee R   28.00 
Radiological procedures 
X-ray 
CT scan 
R 151.00 
R 2 030.00 
Electrocardiogram procedure R 189.00 
Emergency room fee R 400.00 
Hospitalisation fee per day R 1 430.00 
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4.10  Cost components studied  
The cost components which impact the direct medical costs of treating diabetes mellitus and 
its complications were taken into account during the study. The cost components represent 
the resources which were utilised in the treatment of diabetes mellitus and its complications. 
The following cost components were included: 
a) Outpatient doctor consultations; 
b) Pharmacy supplies; 
c) Laboratory tests; 
d) Radiological and electrocardiography procedures; 
e) Emergency room visits; 
f) Inpatient hospitalisations; and 
g) Surgeries. 
4.11  Categorisation of costs  
The costs were categorised into two categories: 
a) costs due to diabetes mellitus; and 
b) costs due to the complications of diabetes mellitus.  
All costs which had a link to diabetes mellitus and its complications were included in one of 
the two categories of cost. These costs were categorised based on the clinical profile of the 
disease. Costs due to the complications of diabetes mellitus, were costs due to the 
complications of diabetes mellitus only and did not include diabetes mellitus cost. 
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4.11.1  Outpatient doctor consultation  
Outpatient doctor consultations due to diabetes mellitus had either an ICD-10 code or a 
recorded diagnosis of diabetes mellitus. This was classified as an outpatient consultation cost 
due to diabetes mellitus.   
Outpatient doctor consultations due to the complications of diabetes mellitus either had an 
ICD-10 code or a recorded diagnosis which related to a complication of diabetes mellitus. 
Patients who visited specific clinics at Groote Schuur hospital, which related to the 
complications of diabetes mellitus, were recorded as consultations due to the complications 
of diabetes mellitus. This was classified as outpatient consultation costs due to the 
complications of diabetes mellitus. 
4.11.2  Pharmacy supplies  
These included the items which patients obtained from the pharmacy department at Groote 
Schuur hospital. These were divided into four distinct categories i.e., insulin, oral 
hypoglycaemic agents, medicines for the treatment of the complications of diabetes mellitus 
and diagnostic agents. The cost of needles and syringes used to administer insulin were 
included as part of the insulin cost. Diagnostic agents included blood glucose test strips.  
The medicine classes used to treat the complications of diabetes mellitus are indicated in 
Table 7. The cost for these medicines was categorised as costs due to the complications of 
diabetes mellitus. 
Costs due to diabetes mellitus included insulin, oral hypoglycaemic agents and blood glucose 
test strips. The dispensing fee was included in the cost due to diabetes mellitus as patients 
would have to collect medicines regardless of whether or not they had a complication. 
Therefore the dispensing fee is attributed as a cost due to diabetes mellitus. 
 
 
 
 
34 
 
Table 7   Medicine classes used to treat the complications of diabetes mellitus 
Anti-coagulants Calcium channel blockers 
ACE-inhibitors Diuretics 
Alpha blockers Fibrates 
Aldosterone antagonists Ophthalmic preparations 
Angiotensin II inhibitors Nitrates 
Beta blockers Statins   
 
4.11.3   Laboratory tests 
Laboratory tests were divided into two distinct categories i.e., routine laboratory tests and 
laboratory tests conducted due to the treatment of the complications of diabetes mellitus. 
Routine laboratory tests were those tests that were usually conducted at every visit to Groote 
Schuur hospital. These tests included the blood glucose and glycated haemoglobin tests. 
Laboratory tests conducted due to the treatment of the complications of diabetes mellitus are 
indicated in Table 8. 
Table 8 Laboratory tests conducted due to the treatment of diabetes mellitus 
related complications 
Albumin  Full blood count including platelet  
Calcium  Microalbumin in urine  
Cholesterol HDL  Phosphorous 
Cholesterol total  Potassium  
Creatine kinase  Profile discrete analyser urea & electrolyte 
Creatinine  Sodium 
Creatinine – Automated Triglyceride 
Erythrocyte sedimentation rate (ESR)  Total protein  
Urea   
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Laboratory test costs attributed to diabetes mellitus were those costs for routine laboratory 
tests. The remaining laboratory test costs were attributed to the costs associated with the 
treatment of the complications of diabetes mellitus.  
For patients who had no diabetes mellitus related complications but had laboratory tests 
referred to in Table 8, these costs were attributed to diabetes mellitus. It was assumed that 
these were conducted to screen for the complications of diabetes mellitus.  
For patients who had diabetes mellitus related complications and for whom laboratory tests 
were conducted that did not match their specific complications, these costs were attributed to 
the complications of diabetes mellitus. It has been documented that patients with diabetes 
mellitus complications are at risk of developing other complications related to diabetes 
mellitus (Zhao et al. 2008; Girach et al. 2006). 
4.11.4  Radiological and electrocardiography procedures  
The costs of radiological and electrocardiography procedures were attributed to the 
complications of diabetes mellitus. These were commonly performed procedures at Groote 
Schuur hospital when managing diabetes mellitus patients with complications. 
For patients who did not have diabetes mellitus related complications and for whom 
radiological and electrocardiography procedures were performed, these costs were attributed 
to diabetes mellitus. These were noted as screening procedures.  
4.11.5  Emergency room visits  
Emergency room visits which were due to the complications of diabetes mellitus either had 
an ICD-10 code or a recorded diagnosis which related to a diabetes mellitus complication. 
The costs of these visits were attributed to the complications of diabetes mellitus. 
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4.11.6  Inpatient hospitalisations 
Inpatient hospitalisations which were due to the complications of diabetes mellitus either had 
an ICD-10 code or a recorded diagnosis which related to a diabetes mellitus complication. 
The costs of these visits were attributed to the complications of diabetes mellitus. 
4.11.7  Surgeries  
Surgeries which were due to the complications of diabetes mellitus either had an ICD-10 
code or a recorded diagnosis which related to a diabetes mellitus complication. The costs of 
this visit were attributed to the complications of diabetes mellitus. 
4.12  Cost template 
The cost template was developed using an Excel 
® 
spreadsheet and all patient data were 
entered into the spreadsheet. The cost template provided the framework for which patient 
costs were recorded, calculated and analysed. The cost was reported for the 20 month study 
period. This cost template was structured in two parts as discussed below, i.e. costs for 
diabetes mellitus and the complications of diabetes mellitus. The fields which were 
developed for this cost template are presented in Annexure 3(page 111). 
4.12.1  Cost template for diabetes mellitus 
The following cost components were used to quantify the direct medical costs associated with 
treating diabetes mellitus: outpatient doctor consultations, pharmacy supplies and laboratory 
tests. 
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4.12.2  Cost template for the complications of diabetes mellitus 
The following cost components were used to quantify the direct medical costs associated with 
treating the complications of diabetes mellitus: outpatient doctor consultations, pharmacy 
supplies, laboratory tests, radiological and electrocardiography procedures, emergency room 
visits, inpatient hospitalisations and surgeries. 
4.13  Cost calculation 
The fees which are referred to as UPFS were derived from UPFS Provincial Gazette for 
Western Cape, No. 6862, 25 March 2011. The cost was calculated for each patient for the 20 
month study period and the total cost for all the patients was calculated. In addition, an 
average cost per patient was calculated.  
4.13.1   Outpatient doctor consultations cost 
The unit cost per consultation was multiplied by the number of consultations per patient to 
obtain a cost per patient.  
4.13.2  Pharmacy supplies cost 
The unit cost for each medicine was multiplied by the quantity dispensed for each medicine 
to obtain a cost per patient. A similar approach was used for diagnostic tests.  
The dispensing fee (UPFS) was billed per prescription issued per day at Groote Schuur 
hospital. A patient would only be charged the dispensing fee once regardless of the number of 
prescriptions obtained on the same day. This is different to the practice in the private sector, 
where the dispensing fee is dependent on the number of items per prescription. The 
dispensing fee unit cost was multiplied by the number of prescription collection days per 
patient and a cost per patient was calculated for the study period. 
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4.13.3  Laboratory test cost 
Each laboratory test had a unit cost and the cost for laboratory tests per patient was 
calculated. 
4.13.4  Radiological and electrocardiography procedure cost 
Each procedure had a unit cost (UPFS) and the cost for radiological and electrocardiography 
procedures per patient were calculated. 
4.13.5  Emergency room visit cost 
The cost for an emergency room visit consisted of the following components: 
a) cost of the emergency room consultation; 
b) cost of the laboratory tests conducted during the emergency room visit; and 
c) cost of radiological and electrocardiography procedures conducted during the 
emergency room visit. 
The cost per emergency room visit per patient was calculated based on the above 
components.  
4.13.6  Inpatient hospitalisation cost 
The cost for an inpatient hospitalisation consisted of the following components: 
a) cost of the inpatient hospitalisation per day multiplied by the length of stay; 
b) cost of the laboratory tests conducted during the hospitalisation; and 
c) cost of radiological and electrocardiography procedures conducted during the 
hospitalisation. 
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The cost per hospitalisation per patient was calculated based on the above components. 
4.13.7  Surgery cost 
The cost for surgery consisted of the following components: 
a) cost of the anaesthesia; and 
b) cost of the theatre.  
The cost for the surgery per patient was calculated. 
4.13.8  Cost per patient 
The cost of treatment for diabetes mellitus and the complications of diabetes mellitus were 
separately calculated for each patient, using the sum of the component costs to obtain a cost 
per patient. 
4.13.9  Total cost 
The total cost of treatment for all the patients for the study period was calculated by adding 
the cost for each patient. This cost was calculated at both patient and cost component levels. 
The total cost per cost component for all patients was also obtained.  
4.13.10 Average cost per patient 
The average cost per patient was calculated at both the patient and cost component levels. 
The average cost per patient was obtained by dividing the total cost by the number of 
patients. The average cost per patient for each cost component was obtained by dividing the 
total cost per component by the number of patients who utilised that particular component. 
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4.14  Cost methods developed 
This study developed two cost methods: 
a) Combined method i.e., using data from the electronic patient records and patient 
folders; and 
b) Electronic method i.e., using data from the electronic database only. 
4.14.1  Combined method 
This method utilised data from electronic database (primary source) and patient folders. The 
purpose for this combination has been described in section 4.6 and 4.7. This method has been 
described throughout Chapter 4. 
4.14.2 Method to determine the costs associated with diabetes mellitus and its 
complications using the electronic database only 
A method was developed which determined the direct medical costs associated with diabetes 
mellitus and its complications at Groote Schuur hospital, using data from the electronic 
database only.  This method is referred to as the electronic method.  
Table 9 summaries the problems associated with this database and solutions which were used 
to overcome these problems. 
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Table 9  Problems with the electronic database and solutions 
Incomplete information Solution to the problem 
Type of diabetes mellitus Use the medicine history to categorise the type of 
diabetes mellitus 
Identification of complication Based on laboratory tests conducted AND specialist 
consultations, clinics visited at GSH 
Type of complication Specialist consultations and clinics visited at GSH 
Incorrect medicine costs Obtain costs from GSH pharmacy department based 
on tender prices 
Reason for hospitalisation Assumption
1
 
Reason for emergency room visit Assumption
1
 
1 All hospitalisations and emergency room visits were due to diabetes mellitus and/or its complications. 
 
The method which was developed to determine the costs for diabetes mellitus and its 
complications using the electronic database only was tested. The same sample of 100 patients 
as used for the combined method was used in this analysis but using data obtained only from 
the electronic database. The following procedure was used: 
a) patient identifiers were removed from the database and only hospital numbers were 
left. This was to remove any bias and prior knowledge which the researcher had as the 
same 100 patients whose folders were perused were used in this analysis;   
b) using the patient hospital numbers, all data for the study period was extracted from 
the electronic database; 
c) data were entered into the framework of the cost template; 
d) patient’s medicine history was used to categorise patients into two categories, (1) 
insulin dependent diabetes mellitus and (2) non-insulin dependent diabetes mellitus; 
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e) a diagnosis of a complication of diabetes mellitus was assumed if the following 
criteria were met: 
a. history of doctor consultations which had a reason associated with the 
complications of diabetes mellitus; 
b. a visit to one of the following clinics, which relate to the complications of 
diabetes mellitus: 
i. ophthalmology; 
ii. nephrology; 
iii. venous;  
iv. amputation; and 
v. neurology. 
f) laboratory tests mentioned in Table 8 (page 34); 
g) health care resources used during the study period were allocated costs (as explained 
in section 4.13); and 
h) costs were categorised into (1) costs due to diabetes mellitus and (2) costs due to the 
complications of diabetes mellitus, as mentioned in section 4.11. 
 The results obtained were compared to the results obtained using the combined method. 
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4.15  Predictive cost model  
4.15.1  Decision tree model 
A model was developed which used a decision tree to predict costs in a diabetic population. 
The following categories were used in the decision tree: 
a) Type I diabetes mellitus with no complications 
b) Type I diabetes mellitus with complications 
c) Type II diabetes mellitus with no complications 
d) Type II diabetes mellitus with complications 
Probabilities of the occurrence of the types of diabetes mellitus and its complications and the 
costs derived from the combined method when these events occur were used in a decision 
tree. The purpose of this analysis was to predict the costs of diabetes mellitus and its 
complications at Groote Schuur hospital. These costs were then compared with those costs 
derived using the combined method. The same sample of 100 patients was used in the 
decision tree. The cost per event can be predicted by multiplying the cost estimate for the 
particular outcome by the outcome probability. The total cost for the diabetic population can 
be obtained by the sum of these costs. The costs per year were used in this analysis. 
4.15.2  Potential costs incurred at other health facilities during the study period 
The purpose was to develop a method for a model which incorporated additional costs which 
the study population could have incurred during the study period at other hospitals besides 
Groote Schuur hospital i.e. community health centres (CHC). This model was developed by 
simulating the utilisation of the following health care resources at the CHC: doctor 
consultations, medicine collections and laboratory tests.  
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The model was developed for health care services which were used routinely and took into 
account resources which were utilised at Groote Schuur hospital. 
The following process was followed in developing this model: 
a) The patient’s duration in the study was calculated by determining an index point for 
each patient. The index point was the first date at which the patient was identified in 
the electronic database during the study period; 
b) The number of months from the index point until the end of the study period was 
determined for each patient; 
c)  The following was assessed for the study period: 
a. number of doctor consultations required; 
b. number of medicine collections required; and 
c. laboratory tests required and the time intervals for these tests. 
d) The model determined which of the above mentioned resources were utilised at 
Groote Schuur Hospital and the time intervals thereof; 
e) Based on the data obtained from Groote Schuur hospital for the patients, it was then 
determined which resources would have been utilised at community health centres 
and the frequency thereof. The following assumptions were based on expert view 
(Prof Levitt): 
a. Doctor consultations and medicine collections will occur on a monthly basis; 
and 
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b. Laboratory tests will be conducted at specific time intervals. It was assumed 
that the laboratory tests not conducted at Groote Schuur hospital would be 
conducted at the CHC. 
Patients would be classified into two categories, stable and unstable patients. The health care 
resource utilisation assumptions for these categories of patients were based on expert view 
(Prof Levitt) and are presented in Table 10. 
Table 10  Health care resources used and the time intervals thereof 
Health care resource Time interval for utilisation for 
stable patients 
Time interval for 
utilisation for unstable 
patients 
Specialist consultations Every 6 months Every 3 months 
Doctor consultations Every 3 months Every month 
Medicine collections Every month Every month 
Blood glucose tests Every 3 months Every month 
Laboratory tests: 
Routine Every 6 months Every 3 months 
Tests conducted due to diabetes 
mellitus complications 
Every 6 months Every 3 months 
 
Various health care resources were utilised at Groote Schuur hospital during the study period 
e.g. doctor consultations, medicine collections and laboratory tests. These were health care 
services utilised routinely, either monthly or at defined time intervals.  
Health care services such as electrocardiogram and radiological procedures, emergency room 
visits, inpatient hospitalisations and surgery were only utilised in emergency situations and 
would therefore occur less frequently as compared to the health care services mentioned 
above. The functionality of this method was tested in a sample of 10 patients and both 
categories were used i.e. stable and unstable patients as indicated in Table 10. 
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4.15.2.1 Model costing 
The costing of this model was based on patient specific simulated data points. This included 
doctor consultations, medicine collections and laboratory tests which could have been 
conducted at the CHC. In addition, the actual costs obtained from Groote Schuur hospital 
were incorporated into the model.  
The total cost for each patient consisted of simulated costs at the community health centres 
and actual costs at Groote Schuur hospital. Table 11 refers to the various cost components 
used in this model to obtain the final total cost. 
TABLE 11 Cost components at Groote Schuur hospital and community health centre 
Cost components at Groote Schuur hospital Cost components at community health centres 
Doctor consultations  Doctor and/or nurse consultations 
Pharmacy supplies  Pharmacy supplies 
Laboratory tests Laboratory tests 
Electrocardiogram and radiological procedures 
Emergency room visits  
Hospitalisations 
Surgeries 
 
The cost for consultations was presented in two parts, viz. either a cost for a consultation with 
a doctor or a nurse as depending on the community health centre, the patient would either see 
a nurse or a doctor. The unit cost per consultation (either doctor or nurse) was obtained from 
the UPFS fee schedule and then multiplied by the number of consultations which could have 
been conducted at the community health centre.  A cost for a consultation with a doctor or a 
nurse was calculated. This was done by multiplying the unit cost per consultation (doctor or 
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nurse) by the number of consultations which would have been conducted at the CHC. This 
cost was presented as a range between the two health care professionals. 
The cost for medicines was presented in two parts, the medicine cost and the dispensing fee 
at the community health centre. For each patient, the average cost per prescription was 
calculated. This was done by using the actual patient medicine data obtained from Groote 
Schuur hospital, the total medicine cost per patient and dividing it by the number of medicine 
collections. The average medicine cost was then multiplied by the predicted number of 
medicine collections at the community health centre. The unit cost for the dispensing fee was 
multiplied by the number of medicine collections at the community health centres. These 
costs combined represented the medicine cost for the patient at the community health centre. 
The unit cost for each laboratory test was obtained from the National Health Laboratory 
Service (NHLS). This unit cost was then applied to the specific laboratory tests which 
according to the model could have been conducted at the community health centres. 
The model consisted of two distinct costs i.e., the actual cost from Groote Schuur hospital 
and the simulated cost from the community health centre. These two costs provided the total 
cost of diabetes mellitus and its complications for each patient for the study period.  
The cost for each patient was standardised to a 12 month period, by determining the cost per 
month for each patient based on the number of months the patient was in the study. This 
figure was extrapolated to a cost per year. 
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4.15.2.2 Model assumptions 
The model made the following assumptions: 
a) the patients did visit other health care facilities when they did not come to Groote 
Schuur hospital during the study period; 
b) resources such as emergency room visits, hospitalisations and surgeries for this 
population were utilised at Groote Schuur hospital only during the study period; 
c) no additional laboratory tests, electrocardiogram and radiological procedures, and 
doctor consultations were conducted during the study period at other health facilities 
which were outside the standard treatment guidelines;  
d) the patient’s medication did not change during the study period; and 
e) 70% compliance with regard to collection of medicines. 
These assumptions are in addition to the criteria set out in Table 10 which describe the 
category of patients and the frequency with which specific health care services would be 
utilised at the community health centres.  
4.16 Total cost of diabetes mellitus and its complications using sample of 1094 
patients 
The full sample of 1094 patients was used in this analysis to obtain the best possible cost 
estimates. Data from the electronic database were used to determine the total cost of diabetes 
mellitus and its complications. Hospitalisations and emergency room visits which had reasons 
related to diabetes mellitus and its complications recorded in the database were included in 
the cost analysis.  
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The cost was obtained for each cost component and a cost per patient was obtained. Due to 
the inconsistencies within the database costs could not be attributed to diabetes mellitus or 
diabetes mellitus complications accurately. Therefore total cost for diabetes mellitus and its 
complications was presented. 
4.17  Patient data analysis 
The patient data were arranged into four main sub-groups: 
1. type I or type II diabetes mellitus; 
2. diabetes mellitus or diabetes mellitus with complications; 
3. number of doctor consultations at Groote Schuur Hospital 
a. 5 or less or 6 or more; and  
4. number of visits to GSH, irrespective of doctor consultations 
a. 5 or less or 6 or more. 
The total and average cost per patient for each sub-group of patients was calculated. This cost 
was presented in two parts, a cost per 20 month study period and a cost per year. 
Patients were divided into two groups based on the number of visits to Groote Schuur 
hospital. As Groote Schuur hospital is a tertiary facility, patients would receive their routine 
care at lower level facilities. The frequency with which the study patients visited Groote 
Schuur hospital varied. Therefore the patients were then grouped according to the number of 
visits for the cost analysis.   
For the purpose of this study a visit was defined as a visit to any one of the following 
departments at Groote Schuur hospital: pharmacy department, inpatient hospitalisation, 
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emergency room and surgery at any point during the study. These visits occurred on different 
dates, if a patient visited more than one department on the same date, then it was noted as one 
visit. Patients were also grouped based on the number of consultations with the doctor at 
Groote Schuur hospital. The patients were further grouped according to the type of diabetes 
mellitus and whether they had a diabetes mellitus related complication or not.  
4.18  Statistical analysis 
Statistical analyses were used to describe the results which were obtained. Non-parametric 
statistical analyses were used due to the small sample sizes of the various sub-groups. The 
median is usually nearly equal to the average for the various sub-groups, however, some 
monetary means displayed long-tailed distributions towards the larger amounts, thus making 
the medians differ from the means. Therefore, the cost data was presented as means and 
medians. The Number Cruncher Statistical System (NCSS. 2001) was used to analyse the 
following cost data for statistical differences. The following groups (1) type I versus type II 
diabetes mellitus and (2) diabetes mellitus versus diabetes mellitus with complications, were 
compared for statistical differences using the Kruskal-Wallis test (non-parametric ANOVA 
statistical test) and z-values greater than 1.96 were considered to be statistically significant.  
The Kruskal-Wallis test was used in this study due to the following: (1) the groups which 
were examined were unequal in size, (2) the groups are independent and not related and (3) 
the distribution is skewed and not symmetrical. The differences in cost obtained between the 
combined and electronic method were analysed using Fisher’s exact test to determine 
whether the differences were statistically significant or not. P-values less than 0.05 were 
considered statistically significant. Fisher’s exact test was used in this study due to the 
following: (1) the small sample size and (2) the same sample of patients was used but two 
different cost methods were applied.  
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4.19  Ethics 
Approval for this study was obtained from the Research Ethics Committee of the University 
of the Western Cape (Ref: ScRIRC2010/09/08) and the Human Research Ethics Committee 
of the Faculty of Health Sciences, University of Cape Town (HREC ref: 416/2010). 
Additional approval was obtained from the Western Cape Provincial Department of Health to 
conduct the study at Groote Schuur hospital.  Patient records were only accessible to the 
researchers (Prof P. Valodia and S. Nomame) directly involved in the study. Patient 
confidentiality was maintained at all times. 
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CHAPTER 5 
RESULTS 
The focus of this chapter is on the cost results obtained using the combined method. The 
results obtained using the combined and electronic methods were compared and analysed for 
statistically significant differences. The costs for the various sub-group analyses are 
presented, using data from the combined method. This chapter also highlights the various 
methods which were developed to cost the management of diabetes mellitus and its 
complications at Groote Schuur hospital. 
Data for 100 patients were included in the study as depicted in Figure 1. There were 67.3% of 
the patient folders missing from the Medical Records department. Patient folders were 
requested from the Medical Records department until a sample of 100 patients was achieved. 
There were 8 patient folders which did not meet the selection criteria. Patients who attended 
the adult diabetic clinic were extracted from the electronic database and it was found that out 
of the convenient sample selected (of patient folders available) only 0.93% of the patients 
were not diabetic. This result indicates that this could be an alternative method of extracting 
patients from electronic databases as opposed to using ICD-10 codes. 
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Figure 1 Patient selection  
5.1 Patient characteristics 
Table 12 provides information on the patient characteristics of the 100 patients who were 
selected from the electronic database. Seventy-two percent (72%) of the patients were type II 
diabetics and 28% were type I diabetics. 
 
 
 
 
 
330 patients 
conveniently selected 
out of 1094 patient 
records 
8 excluded: 
3 cancer co-morbidity 
4 alcohol induced 
diabetes mellitus 
1 non-diabetic patient  
222 patient folders 
missing and/or 
unavailable during 
the data collection 
period 
 
100 patients 
included in the 
study 
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Table 12 Patient characteristics  
Number of patients 100 
Number of male patients 41 
Number of female patients 59 
Number of type I diabetes mellitus patients 28 
Number of type II diabetes mellitus patients 72 
Average age (±) of patients (years) 51.81 (± 13.84) 
Age range of patients (years) 22 – 81  
 
Table 13 indicates the other disease conditions which affected the patients. These are defined 
as co-morbid conditions and differ from the complications of diabetes mellitus. Table 13 
indicates that hypertension and dyslipidaemia were the highest ranking co-morbid conditions 
in this study population, 66% and 52%, respectively. This result also shows that these 
patients suffered from hypertension and dyslipidaemia concomitantly. 
Table 13  Patient co-morbidities (n=100) 
Co-morbidity % of patients 
Hypertension 66 
Dyslipidaemia 52 
Arthritis 5 
Asthma 5 
Depression 4 
Other 21 
 
The other co-morbid conditions were chronic hepatitis C, epilepsy, glaucoma, Human 
Immunodeficiency Virus, liver dysfunction, hypothyroidism, menopause, pancytopenia, 
psoriasis and tuberculosis. These affected 21% of the patients. 
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Table 14 indicates the frequency of use of diabetes mellitus medicines by the study 
population. Insulin and metformin were the most commonly used diabetes mellitus 
medicines. There were 61 (84.7 %) of the type II diabetics on insulin and oral hypoglycaemic 
medicines. This large figure was due to the fact that patients who attended Groote Schuur 
hospital were those whose diabetes mellitus was poorly controlled on oral hypoglycaemic 
medicines. 
Table 14  Frequency of anti-diabetic medicines used by the study population 
Medicine (Generic name) Number of patients 
Glibenclamide 5 
Gliclazide 21 
Metformin 67 
Insulin 89 
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5.2 Diabetes mellitus complications 
5.2.1 Types of diabetes mellitus complications 
Table 15 Frequency of the various types of diabetes mellitus complications 
Type of complication Percentage of patients 
Microvascular 
Neuropathy 48% 
Nephropathy 45% 
Retinopathy 27% 
Macrovascular 
Ischaemic heart disease (IHD) 21% 
Peripheral vascular disease (PVD) 5% 
Acute  
Acute metabolic complications  16.7% 
 
Table 15 indicates the type of diabetes mellitus complications found in the study patients and 
the frequency thereof amongst type I and type II diabetes mellitus patients. Microvascular 
complications of diabetes mellitus were the most frequently occurring, with neuropathy 
ranking the highest, affecting 48 % of the study population. Ischaemic heart disease (IHD) 
was the most common macrovascular complication of diabetes mellitus. In the study 
population the chronic complications of diabetes mellitus were more common than the acute 
metabolic complications. The acute metabolic complications are reversible and are mainly 
treated at secondary and primary level hospitals. These patients would not necessarily be 
referred to Groote Schuur Hospital. The acute metabolic complications of diabetes mellitus 
mainly affected the type I diabetic patients.  
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5.2.2 Number of diabetes mellitus complications 
Patients who had complications related to diabetes mellitus consisted of 77% of the study 
population as shown in Table 16.  
Table 16  Number of diabetes mellitus complications 
Number of complications % of patients affected 
No complications 23% 
1 complication 27% 
2 complications 30% 
3 complications 15% 
4 complications 5% 
 
Of the patients who had diabetes mellitus complications, it was found that 64,9% of these 
patients had two or more diabetes mellitus complications as indicated in Table 16. Groote 
Schuur hospital is a tertiary level facility and therefore it is not uncommon for a high 
proportion of these patients to suffer from complications of diabetes mellitus. 
In this study it was found that 64.3% and 82% of type I and type II diabetes mellitus patients, 
respectively, had complications due to diabetes mellitus.  
5.2.3 Number of complications and age of patients 
As indicated in Figure 2, the number of complications a patient suffers from follows an 
increasing trend as the patient age increases. 
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Figure 2  Number of complications versus patient age 
5.3  Development of costing method 
A successful method was developed using the electronic database and patient folders 
(combined method). The cost results presented in this chapter utilise data from the combined 
method of costing. The results from the electronic method of costing are presented as a 
comparison to the results obtained using the combined method. 
5.4 Cost of diabetes mellitus and its complications 
The costs associated with the treatment of diabetes mellitus and its complications are reported 
in Table 17. All costs are reported in South African Rands (R) for the study period.  
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5.4.1 Total cost of diabetes mellitus and its complications 
Table 17 represents the cost associated with diabetes mellitus and its complications for the 20 
month study period and also expressed as a cost per year. The data presented in Table 17 
were taken from the combined method 
Table 17 Total cost of diabetes mellitus and its complications 
Cost component Cost (20 months) Cost per year 
Diabetes mellitus (n=100)
1
 R 179 675.06 (39.3%) R 107 805.04 
Diabetes mellitus complications 
(n=77)
2
 
R 277 792.28 (60.7%) R 166 675.37 
   
Total
3
 R 457 467.34 R 274 480.41 
1 Cost due to the management for diabetes mellitus only, all patients in the study had costs due to diabetes mellitus only. 
2 Cost due to the management of the complications of diabetes mellitus (excluding diabetes mellitus). 
3 Total cost for diabetes mellitus and its complications. This cost is the sum of diabetes mellitus and diabetes mellitus 
complications with no overlap in cost. 
 
 
Table 17 indicates that 100 patients had costs due to diabetes mellitus and of these patients 77 
had complications and costs due to these complications. This result indicates that the 
complications of diabetes mellitus cost 1.5 times more to treat than diabetes mellitus. The 
complications of diabetes mellitus contributed 60.7% of the total cost. This result shows the 
impact of diabetes mellitus complications on the total cost of treatment.  
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Table 18  Total costs of the various cost components 
Cost component Cost 20 months (%) Number of items Cost per year 
Consultations (outpatient) R 101 702.00 (22.2%) 422 R 61 021.20 
Pharmaceutical supplies R   95 143.92 (20.8%) 1642 R 57 086.35 
Laboratory tests R   86 750.42 (19%) 2044 R 52 050.25 
Electrocardiogram procedures R     6 048.00 (1.3%) 32 R   3 628.80 
Radiological procedures R     8 656.00 (1.9%) 26 R   5 193.60 
Emergency room visits
1
 R     6 000.00 (1.3%) 15 R   3 600.92 
Hospitalisations
1
  R 108 680.00 (23.8%) 16 R  65 208.05 
Surgery R   44 487.00 (9.7%) 6 R  26 692.20 
    
Total  R 457 467.34  R 274 481.41 
1Does not include costs for laboratory, electrocardiogram and radiological procedures conducted during these events. 
Table 18 indicates the various costs for each cost component in the study. Emergency room 
visits and hospitalisation cost do not include costs for laboratory tests, radiology and 
electrocardiogram procedures conducted during those events as these have been reported 
separately. 
Consultations, pharmacy supplies, laboratory tests and hospitalisation contributed 22.2%;   
20.8%; 19% and 23.8%, respectively, of the total cost. When evaluating the cost per patient 
for the various cost components, then hospitalisation and surgery costs were R 8 360.00 and       
R 7 414.50, respectively. These were main cost drivers on a per patient basis.   
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Table 19 List of each hospitalisation during study period 
Reason for hospital visit Number of 
hospitalisations 
Frequency of 
hospitalisation 
(%) 
Length of stay (days) 
Hypoglycaemia 1 6.3% 1 
Hypoinsulinaemia 1 6.3% 11 
Diabetic coma 1 6.3% 4 
Uncontrolled diabetes mellitus 1 6.3% 7 
Diabetic cataract 1 12.5% 2 
Diabetic cataract 1 2 
Diabetic foot ulcer 1 6.3% 3 
Peripheral vascular disease 1 6.3% 20 
Ischaemic heart disease  1 6.3% 1 
Stroke  1 6.3% 3 
Hospitalisations due to surgery 
Day surgery (diabetic cataract) 1 25% ½ 
Day surgery (diabetic cataract) 1 ½ 
Day surgery (diabetic cataract) 1 ½ 
Day surgery (diabetic foot) 1 ½ 
Diabetic foot ulcer including surgery 1 6.3% 7 
Infection following surgery for 
diabetic foot 
1 6.3% 14 
 
Table 19 indicates the various hospitalisations which occurred during the study period. 
Hospitalisations due to the acute metabolic complications of diabetes mellitus and day 
surgery were 25.2% and 25%, respectively, of the hospital events. During the 20 month study 
period, there was only one hospital event due to stroke. Peripheral vascular disease which 
results from neuropathy (most commonly occurring diabetes mellitus related complication), 
had the highest number of hospital days. As this was only one case, no conclusions should be 
derived from this result. Hospitalisations are unique and the length of stay will be different 
for each patient. Various factors such as duration of diabetes mellitus, levels of haemoglobin 
A1c, presence of co-morbid conditions and risk factors (Pagano et al. 2007) affect 
hospitalisation. 
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Hospitalisations due to diabetic cataract accounted for 37.5% of the total hospital events,     
60% of these were due to day surgery. This was expected as Groote Schuur hospital is a 
tertiary level institution and patients would be referred here for specialised treatment. 
Consultations contributed 22.2% of the total cost and all the patients utilised this resource. 
There were a total of 422 consultations during the study period. The percentage of 
consultations due to the complications of diabetes mellitus was 40.5%.  
The percentage contribution of pharmaceutical supplies and laboratory tests to the total cost 
was 20.8% and 19 % respectively. These resources were utilised by 98% of the patients. The 
data presented in Table 19 were derived from the combined method. 
5.4.2 Cost per patient for diabetes mellitus and its complications 
Table 20  Cost per patient 
Cost component Average cost Median cost Cost per year 
20 month period 
Diabetes mellitus (n=100) 
1
 R  1 796.75     
SD R 972.83 
(R 310.37 - R 6 298.82)                                                                   
R 1 625.50 R  1 078.05                                                                       
Diabetes mellitus complications 
(n=77) 
2
 
R  3 753.95  
SD R 7 806.94 
(R 58.81 - R 48 634.74)                                                                       
R 789.18 R  2 252.37                                                                        
    
Total 
3,4
 R  4 574.67    
SD R 6 935.53  
(R 682.45 - R 49 720.74)                                                                     
R 2 845.42 R  2 744.80                                                                     
1 Average cost per patient due to diabetes mellitus only, all patients had costs due to diabetes mellitus. 
2 Average cost per patient due to the complications of diabetes mellitus (excluding diabetes mellitus). 
3 Average cost per patient for diabetes mellitus and its complications. This is an average cost per patient for the entire sample 
of patients, calculated by the total cost divided by 100 patients. 
4Total average cost is not the sum of average diabetes mellitus and diabetes mellitus complications cost. 
 
  
Table 20 indicates the average cost per patient for the 20 month study period, also expressed 
as an average cost per year per patient. The range, standard deviation and median for the 20 
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month study period are presented Table 20. The complications of diabetes mellitus contribute 
82.1 % of the average cost of treating a patient at Groote Schuur hospital. 
The large difference observed between the median and average cost in the total and diabetes 
mellitus complications cost, was due to the long-tailed distribution of the cost. The data 
presented in Table 20 were derived from the combined method. 
Table 21  Cost per patient for the various cost components 
Cost component Number of 
items 
Average cost Median cost Cost per year 
20 month period 
Consultations 422 R 1 017.02         
SD R 731.13 
(R 241 – R 4 820)                                                           
R 723.00 R   610.21                                                                   
Pharmaceutical supplies 1642 R 980.87    
SD R 813.11 
(R 38.58 – R 4 178.04)                                                                        
R 710.31 R   588.52                                                                           
Laboratory tests 2044 R 876.27          
SD R 466.48 
(R 97.36 – R 2 782.19)                                                                  
R 840.73 R   525.76                                                                           
Electrocardiogram 
procedures 
32 R 232.62 
SD R 97.22 
(R 189 – R 567) 
R 189.00 R   139.57 
Radiological procedures 26 R 541.00        
SD R 710.30 
(R 151 – R 2 181)                                                                     
R 151.00 R   324.60                                                                            
Emergency room visits 15 R 545.45       
SD R 323.62 
(R 400 – R 1 200)                                                                   
R 400.00 
 
R   327.27                                                                       
Hospitalisations  16 R 8 360.00        
SD R 10 856.59 
(R 715 – R 32 890)                                                                 
R 3 575.00 R   5 016.00                                                                       
Surgery 6 R 7 414.50    
SD R 6 365.26 
(R 1 105 – R 17 114)                                                                   
R 4 225.00 R   4 448.70                                                                      
     
Total
1
   R  4 574.67    
SD R 6 935.53  
(R 682.45 - R 49 
720.74)                                                                     
R 2 845.42 R  2 744.80                                                                     
1 Average cost per patient derived from Table 20. The average costs for each of the cost components do not add up to the 
average cost per patient. The average cost per patient per cost component is calculated based on the number of patients 
utilising that particular cost component. 
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Table 21 indicates the average cost per patient for each of the cost components for the 20 
month study period, also expressed as an average cost per patient per year. The range, 
standard deviation and median for the 20 month study period are presented Table 21.  
The average cost per patient hospitalised is 1.8 times more than the average cost per patient 
when taking all the cost components into account. This result shows the large impact which 
hospitalisation has on the cost of treating the complications of diabetes mellitus. The average 
cost per patient for hospitalisation and surgery is more than the average cost per patient when 
taking all the cost components into account. The average costs were calculated only for the 
patients who had utilised those resources. The data presented in Table 21 were derived from 
the combined method. 
5.4.3 Cost of management of diabetes mellitus and its complications at Groote Schuur 
hospital using the electronic method 
The convenient sample of 100 patients was used but only data which were collected from the 
electronic database were used and the method assumptions were applied. The method found 
that 29 % of patients were type I diabetics, 68 % were type II diabetics and in 3 % of the 
patients the diabetes mellitus type was unknown. It was found that 94 % of the patients had 
diabetes mellitus complications. This result was different from the information obtained in 
the folder. This method estimated that an additional 17 patients had diabetes mellitus 
complications. 
The cost of diabetes mellitus and its complications are presented in the Table 22. The total 
cost for each cost component and the average cost per patient for each component for the 20 
month study period are presented. The cost results presented are for the 97 patients who were 
able to be classified as diabetic patients.  
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The percentage of the total cost is presented for the various cost components, as the sum of 
these components represent the total cost. 
Table 22  Cost of diabetes mellitus and its complications using electronic method 
Cost component Total cost  
(% to total cost) 
Average cost per patient Median cost per patient 
20 month period 
Diabetes mellitus 
(n=97)
1
 
R  167 717.85 
(35.8 %) 
R 1 729.05 
SD R 934.02 
(R 310.37 – R 5 867.92) 
R 1 532.12 
Diabetes mellitus 
complications (n=94)
2
 
R  304 567.38 
(64.2 %) 
R 3 274.89 
SD R 7 218.70 
(R 58.81 – R 48 823.74) 
R 1 053.98 
    
Total
3
 R  472 285.23 R 4 868.92 
SD R 7 171.86 
(R 696.13 – R 49 909.74) 
R 2 855.78 
1 Cost due to the management for diabetes mellitus only, all patients in the study had costs due to diabetes mellitus. 
2 Cost due to the management of the complications of diabetes mellitus (excluding diabetes mellitus). 
3 Total cost for diabetes mellitus and its complications. This cost is the sum of diabetes mellitus and diabetes mellitus 
complications, with no overlap in cost. The average costs for each cost component does not add up to the total average cost 
per patient. The average cost per patient per cost component is calculated based on the number of patients utilising that 
particular cost component. 
 
Table 22 indicates that the complications of diabetes mellitus cost 1.8 times more to treat than 
diabetes mellitus. The complications of diabetes mellitus contributed 64.2 % of the total cost 
of diabetes mellitus and its complications. These results can be compared with those 
presented in Table 20 to evaluate the difference in costs obtained when using either the 
combined or electronic method of costing.  
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Table 23  Cost per patient for each cost component using the electronic method 
Cost component Number of 
items 
Total cost (% 
to total cost) 
Average cost per 
patient 
Median cost per 
patient 
20 month period 
Consultations 412 R  99 292.00 
(21.4%) 
R 1 023.63     
SD R 741.21 
(R 241 – R 4 820)                                                                 
R 723.00 
Pharmaceutical 
supplies 
1644 R   95 871.95 
(20.2%) 
R 988.37    
SD R 816.56 
(R 44.46 – R 4 354.52)                                                                          
R 747.75 
Laboratory tests 2037 R   87 061.29 
(18.4%) 
R  897.54       
SD R 465.02 
(R 97.36 – R 2 782.19)                                                                   
R 863.42 
Electrocardiogram 
procedures 
35 R   6 615.00 
(1.4%) 
R 228.10      
SD R 92.86 
(R 198 – R 567)                                                                        
R 189.00 
Radiological 
procedures 
27 R   9 260.00 
(1.9%) 
R 514.44   
SD R 661.41 
(R 151 – R 2 181)                                                                           
R 151.00 
Emergency room visits 16 R  6 400.00 
(1.3%) 
R 581.82 
SD R 414.29 
(R 400 – R 1 600) 
R 400.00 
Hospitalisations 20 R  125 125.00 
(26.3%) 
R 8 937.50 
SD R 10 788.06 
(R 715 – R 32 890) 
R 3 575.00 
Surgery 6 R  44 487.00 
(9.4%) 
R 7 414.50     
SD R 6 365.26 
(R 1 105 – R 17 114)                                                                     
R 4 225.00 
     
Total
1
  R  472 285.23 R 4 868.92 
SD R 7 171.86 
(R 696.13 – R 49 909.74) 
R 2 855.78 
1 Average cost per patient derived from Table 22. The average costs for each of the cost components do not add up to the 
average cost per patient. The average cost per patient per cost component is calculated based on the number of patients 
utilising that particular cost component. 
 
 
There were 20 hospitalisations incurred by 14 patients during the study period. Not all 
hospitalisations had reasons for hospitalisation, therefore, it was assumed that any 
hospitalisations were due to diabetes mellitus. Hospitalisations contributed 26.3 % of the total 
cost and a further 41.1 % of the cost treating the complications of diabetes mellitus.  
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As the same 100 patients were used the results obtained when using the combined method of 
costing can be compared. According to the combined method, the complications of diabetes 
mellitus contributed 60.7% of the total cost whereas the electronic method of costing 
obtained a result of 64.2 %. The Fisher’s exact test indicated that the difference in the total 
cost (diabetes mellitus and complications of diabetes mellitus) was not statistically significant 
(p= 0.41). Furthermore, there was no statistically significant difference (p= 0.64) between the 
diabetes mellitus cost between the two methods. Similarly, the cost due to the complications 
of diabetes mellitus between the two methods was not statistically significant (p= 0.49). This 
result indicates that the electronic method can be used to cost diabetes mellitus and its 
complications at Groote Schuur hospital.  
5.4.4 Cost of diabetes mellitus and diabetes mellitus with complications 
The cost of diabetes mellitus and diabetes mellitus with complications is represented in Table 
24. This data were obtained from the combined method. Patients were separated into 2 
categories i.e., diabetes mellitus only and diabetes mellitus with complications. These were 
two different sub-groups of patients. The cost data obtained in these two groups are 
independent of each other and there is no duplication or overlap in cost. Patients who had 
diabetes mellitus only and diabetes mellitus with complication(s) consisted of 23% and 77%, 
respectively, of the study population. The data presented in Table 24 were derived from the 
combined method. 
 
 
 
 
 
 
 
 
68 
 
Table 24 Cost of diabetes mellitus and diabetes mellitus with complications 
Category Cost Average cost per patient Median cost per 
patient 
Cost per patient 
per year 
20 month period 
Diabetes mellitus 
(n=23) 
R 47 208.97 R 2 052.56 
SD R 1 321.20 
(R 682.45 – R 6 298.82) 
R 1 800.79 R 1 231.54 
Diabetes mellitus 
with complications 
(n=77) 
R 411 784.11 R 5 347.85 
SD R 7 741.56 
(R 792.37 – R 49 909.74) 
R 3 038.08 R 3 208.71 
 
It was found that the cost of managing diabetic patients with complication(s) was 2.6 times 
more than patients with diabetes mellitus only. The Kruskal-Wallis test found that this cost 
difference between diabetes mellitus and diabetes mellitus with complications was 
statistically significant (z = 3.8). The box plot on page 104 of Annexure 2 illustrates the 
distribution of the cost data in this sub-group of patients. 
5.4.5 Cost of pharmacy supplies 
Table 25 indicates the cost associated with the various categories of pharmacy supplies as 
well as the cost of the dispensing fee. This is the cost for the 20 month study period and for 
all the patients who collected medicines at Groote Schuur Hospital (97%). The “number of 
items” column refers to the number of medicine items issued during the study period. 
Table 25  Pharmacy supply cost  
Category Number of items Cost (%) 
Insulin 575 R 28 546.79 (30.1%) 
Oral hypoglycaemic medicines 170 R   3 315.94 (3.5%) 
Medicines used to treat diabetes mellitus 
complications 
765 R 20 397.71 (21.4%) 
Diagnostic agents 132 R 29 443.48 (30.9%) 
Dispensing fee R 13 440.00 (14.1%) 
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Table 25 indicates that insulin and diagnostic agents were the highest contributors to the total 
cost of pharmacy supplies. The acquisition cost for these items is more than the other 
medicines i.e. oral medicines.  The cost of medicines for the treatment of diabetes mellitus 
complications was 21.4% of the total cost. This shows the impact of the complications of 
diabetes mellitus on the cost of pharmacy supplies. The unit cost for the oral hypoglycaemic 
medicines is low when compared to insulin and therefore insulin has a higher cost, even 
though more patients were on oral hypoglycaemic medicines compared with insulin. The data 
presented in Table 25 were derived from the combined method. 
5.4.6 Cost of laboratory tests 
Table 26 Cost of laboratory tests 
Category Number of items Cost Average cost per patient 
20 month period 
Routine laboratory tests (n=99) 945 R 43 955.85 R 444.00 
SD R 250.58 
(R 96.40 – R 1 492.21) 
Laboratory tests conducted due to 
the complications of diabetes 
mellitus (n=69) 
1099 R 42 794.57 R 620.21 
SD R 377.55 
(R 25.27 – R 2 008.11) 
    
Total
1
 2044 R 86 750.42 R 876.27          
SD R 466.48 
(R 97.36 – R 2 782.19)                                                                  
1 Average cost per patient is derived from Table 21. The sum of the average costs per patient for routine lab tests and lab 
tests conducted due to the complications of diabetes mellitus does not add to the average cost per patient, as there is overlap 
in these costs as patients can have costs in both the categories. 
 
 
Laboratory tests conducted due to the complications of diabetes mellitus cost 1.4 times more 
than routine laboratory tests; this can be attributed to the number of tests conducted. As 
would be expected, tests conducted due to the complications of diabetes mellitus were greater 
in number than those conducted due to diabetes mellitus. As indicated in Table 26, the 
number of patients who had tests conducted due to the complications of diabetes mellitus is 
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less than those patients who had routine laboratory tests conducted, therefore resulting in a 
higher average cost per patient when compared to patients having routine laboratory tests. 
The “number of items” column in Table 26 refers to the actual number of tests conducted in 
each category for the study period. The data presented in Table 26 were derived from the 
combined method. 
5.4.7 Cost of emergency room visits and hospitalisations 
Table 27 indicates the cost associated with emergency room visits and hospitalisations, which 
included the costs for laboratory tests, electrocardiogram and radiological procedures 
conducted during these events. The average cost per patient is included for the 20 month 
period. 
Table 27 Cost of emergency room visits and hospitalisations 
Category Number 
of items 
Cost of event Average cost per 
patient
1
 
Cost of lab 
tests, ECG 
and 
radiological 
procedures 
Average cost per 
patient
2
 
20 month period 
Emergency 
room visits 
15 R 6 000.00 R 400.00 
SD R 0 
(R 400 – R 1 200) 
R 5 908.20 R 393.88 
SD R 310.08 
(R 151 – R 2 030.00) 
Hospitalisations 16 R 108 680.00 R 8 360.00        
SD R 10 856.59 
(R 715 – R 32 890)                                                                 
 
R 6 614.08 R 734.90 
SD R 854.79 
(R 244.31 – R 2 954.68) 
1 Average cost per patient for the event, either emergency room visit or hospitalisation. 
2 Average cost per patient for laboratory tests, ECG and radiological procedures conducted during the event (emergency 
room visits or hospitalisation). 
 
As indicated in Table 27, the “number of items” column refers to the number of emergency 
room visits and hospitalisations which occurred during the study period. The data for Table 
27 were derived from the combined method. 
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5.4.8 Cost of type I versus type II diabetes mellitus and its complications 
Table 28 shows the cost of diabetes mellitus and its complications between type I and type II 
diabetic patients. The costs are presented over the 20 month period. The patient data from the 
combined method were grouped according to the type of diabetes mellitus. The costs 
presented in Table 28 refer to this patient sub-grouping and are costs in distinct categories 
i.e., costs due to diabetes mellitus only and costs due to the complications of diabetes mellitus 
only. 
TABLE 28  Average cost per patient for type I versus type II diabetes mellitus and its 
complications 
Cost component Type I diabetes mellitus 
(n=28) 
Median cost Type II diabetes mellitus 
(n=72) 
Median cost 
Cost  (20 months) Cost  (20 months) 
Diabetes mellitus
1
 R  1 975.27 
SD R 1 232.25 
(R 553.93 – R 6 298.82)                                                                      
R 1 499.45 R  1 727.33  
SD R 851.31 
(R 310.37 – R 4 387.08)                                                                      
R 1 666.86 
Diabetes mellitus 
complications
2
 
R  5 326.29 
SD R 10 339.59 
(R 426.58 – R 40 819.65)                                                                     
R 1 611.06 R  3 337.25       
SD R 7 019.22 
(R 58.81 – R 48 823.74)                                                                 
R 1 389.99 
     
Total 
3
 R  5 018.87  
SD R 8 106.52 
(R 723 – R 42 245.81)                                                                   
R 2 938.42 R  4 415.67   
SD R 6 492.94 
(R 682.45 – R 49 909.74)                                                                  
R 2 836.42 
1 Average cost per patient due to the management for diabetes mellitus only. 
2 Average cost per patient due to the management of the complications of diabetes mellitus (excluding diabetes mellitus).  
3 The average cost for each cost component does not add up to the average cost per patient. The average costs per patient per 
cost component are calculated based on the number of patients utilising that particular cost component. 
 
In both groups, the cost of treating the complications of diabetes mellitus is more than 
diabetes mellitus; for type I diabetes mellitus it is 2.7 times more and for type II diabetes 
mellitus it is 1.9 times more. The cost of treating type I diabetic patients is 13.7% more than 
type II diabetic patients. This result shows that type I diabetic patients cost more than type II 
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diabetic patients to treat. Due to the higher acquisition cost of insulin versus oral 
hypoglycaemic medicines, the medicine cost per patient for type I diabetes mellitus should be 
higher than type II diabetes mellitus, but in this case there is only a 13.7% difference in the 
cost. This difference can be due to the number of type II diabetic patients who are on insulin 
and oral hypoglycaemic medicines; 84.7% were on this regimen in this study. The Kruskal-
Wallis test found that the difference in cost between type I and type II diabetes mellitus was 
not statistically significant (z-value = 0.27). The box plot on page 107 of Annexure 2 
illustrates the distribution of the cost data. 
TABLE 29  Average cost per patient for the various cost components for type I versus 
type II diabetes mellitus 
Cost component Type I diabetes 
mellitus (n=28) 
Median cost Type II diabetes mellitus 
(n=72) 
Median cost 
Cost  (20 months) Cost  (20 months) 
Consultations R  1 041.46  
SD R 899.48 
(R241 –R  4 820)                                                               
R 723.00 R  1 007.51 
SD R 661.34 
(R 241 – R 3 856)                                                                   
R 723.00 
Pharmacy supplies R 1  073.63  
SD R 1 025.76 
(R 168.82 – R 4 178.04) 
R 723.18 R   945.08  
SD R 720.23 
(R 38.58 – R 3 610.12)                                                                        
  
R 753.30 
Laboratory tests R    871.67 
SD R 572.58 
(R 193.76 – R 2 782.19)                                                                         
R 763.04 R   877.99  
SD R 424.61 
(R 97.36 – R 2 200.77)                                                                       
R 888.15 
Electrocardiogram 
procedures 
R    378.00 
SD R 267.29 
(R 189 – R 567) 
R 378.00 R   228.38 
SD R 70.72 
(R 189 – R 378) 
R 189.00 
Radiological 
procedures 
R 1  079.33 
SD R 957.05 
(R 453 – R 2 181)                                                                            
R 604.00 R   416.77     
SD R 623.55 
(R 151 – R 2 030)                                                                    
R 151.00 
Emergency room 
visits 
R     666.67 
SD R 413.12 
(R 400 – R 1 200) 
R 400.00 R  400.00 
SD R 0 
(R 400 –R 400) 
R 400.00 
Hospitalisations  R16 683.33  
SD R 15 751.65 
(R 1 430 – R 32 890)                                                                 
R 15 730.00 R 5 863.00  
SD R 8 973.50 
(R 715 – R 30 030) 
R 2 145.00 
Surgery             NONE                                     NONE R  7 414.50  
SD R6 365.26 
(R 1 105 – R 17 114)                                                                  
R 4 225.00 
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Total
1
 R  5 018.87  
SD R 8 106.52 
(R 723 – R 42 245.81)                                                                   
R 2 938.42 R  4 415.67   
SD R 6 492.94 
(R 682.45 – R 49 909.74)                                                                  
R 2 836.42 
1 Average cost per patient derived from Table 28. The average cost for each of the cost components do not add up to the 
average cost per patient. The average cost per patient per cost component is calculated based on the number of patients 
utilising that particular cost component. 
 
Hospitalisation is a key cost driver, in particular for type I diabetic patients. The average cost 
per patient hospitalised is more than the average cost of treating diabetes mellitus and its 
complications per patient when all cost components were taken into account, with this figure 
being 3.3 times more.   
The cost for a period of 12 months was obtained for the following categories: 
TABLE 30 Cost of diabetes mellitus and its complications per year 
Category (n) Cost per year 
Type I diabetes mellitus no complication (n=11) R  15  237.43 
Type I diabetes mellitus with complication(s) (n=17) R  68  599.54 
Type II diabetes mellitus no complication (n=12) R  13  087.96 
Type II diabetes mellitus with complication(s) (n=60) R 178 230.92 
  
Total (n=100) R 275 155.85 
 
The patients were categorised into four groups as indicated in Table 30 and the costs were 
presented as total cost per category i.e., costs due to diabetes mellitus and costs due to the 
complications of diabetes mellitus. These costs were derived from the combined method. 
These costs were used in the decision tree analysis and are different to the costs presented in 
Table 28, which represent costs for sub-grouping of patients according to type of diabetes. 
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There was a 159.8% difference in cost between type I diabetes mellitus with complications 
and type II diabetes mellitus with complications. This was expected, as there were more 
patients with type II diabetes mellitus.  
5.4.9 Impact of number of visits to Groote Schuur hospital on costs  
In our study we assessed what impact the number of visits to Groote Schuur hospital had on 
the cost (as indicated in Table 31) of diabetes mellitus and its complications per patient.  
Table 31 Impact of number of visits and doctor consultations at GSH on cost of 
diabetes mellitus and its complications 
Cost component 5 or less group  6 or more group 
Doctor 
consults
1
(n= 75) 
Visits
2
 (n= 61) Doctor consults
1
      
(n= 25) 
Visits
2
 (n= 39) 
Diabetes mellitus
3
  R 1 728.38 R 1 446.96 R 1 933.51 R 2 343.86 
Diabetes mellitus 
complications
4
 
R 1 875.44 R 1 485.48 R 8 223.06 R 6 455.85 
Total
5
 R 3 028.69 R 2 421.05 R 9 169.80 R 7 972.03 
1 Doctor consultations at GSH, either 5 or less doctor visits or 6 or more doctor visits. 
2 Visits to GSH, irrespective of doctor consultations, either 5 or less visits to GSH or 6 or more visits to GSH. 
3 Cost per patient due to the management for diabetes mellitus only. 
4 Cost per patient due to the management of the complications of diabetes mellitus (excluding diabetes mellitus).  
5 Cost per patient for diabetes mellitus and its complications. The cost of the cost components do not add up to the cost per 
patient. The cost per patient per cost component is calculated based on the number of patients utilising that particular cost 
component. 
 
 
Patients who had 6 or more doctor consultations at Groote Schuur hospital had an average 
cost which was 3 times more than the patient who had 5 or less doctor consultations. This 
result can suggest that patients who have more doctor consultations have more serious 
complications and require more care which, in turn, increases the cost of care. Eighty-eight 
percent (88%) of the patients who had 6 or more doctor consultations at Groote Schuur 
hospital had complications due to diabetes mellitus and 77. 3% of these patients had two or 
more complications of diabetes mellitus.   
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The number of visits influenced the average cost. Patients in the group of 6 or more visits had 
3.3 times more cost than patients in the group of 5 or less visits. The group of 6 or more visits 
had 70.6% of its cost due to diabetes mellitus complications and the group of 5 or less visits 
had 40.2% of its cost due to diabetes mellitus complications. This result emphasises the 
impact of complications on the cost of treatment.   
5.5 Predictive cost models 
5.5.1 Predicting costs using decision tree analysis model 
The results of this model were based on actual costs at Groote Schuur hospital for a 12 month 
period. Table 32 summaries the probabilities of certain events occurring and the costs thereof, 
using data which was obtained from the sample of 100 patients. This data were obtained from 
the combined method. The cost per patient in Table 32 was derived from the costs obtained in 
Table 30 (page 73) for the various categories. 
Table 32  Probabilities of events occurring and cost thereof 
Event occurring Probability of event 
occurring 
Cost of event 
Diabetes mellitus type I 0.28  - 
Diabetes mellitus type I no 
complication 
Diabetes mellitus type I with 
complication(s)  
0.36 R 1 385.22 
 
0.64 
 
R 4 035.27 
Diabetes mellitus type II 0.72  - 
Diabetes mellitus type II no 
complication 
 
Diabetes mellitus type II with 
complication(s)  
0.18 
 
R 1 090.66 
 
0.82 
 
R 2 970.52 
 
The following example illustrates how this algorithm could be used. If a diabetic population 
of 100 patients is treated at Groote Schuur hospital for a period of 12 months using the above 
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probabilities of events occurring and the costs thereof, the financial impact of treating these 
patients can be determined; 100 patients X 0.28 (probability of being type I diabetic) X 0.64 
(probability of type I diabetic patient having a complication) X R 4 035.27 (cost per patient 
per year) = R 72 312.04. 
The costs for four categories are calculated for 100 patients and the sum of these categories 
represents the total cost for the population. 
The total cost for treating these patients over a period of 12 months was R 275 789.51. This 
cost was 0.23% (R 633.66) higher than the actual cost. This result was expected as the cost 
estimates, probabilities of type of diabetes mellitus and complications occurring for the 
various categories were derived from the study. This indicates that this model can therefore 
be applied to predict costs at Groote Schuur hospital. 
The decision tree is represented by Figure 3, and shows the event probabilities and cost 
estimates for certain events.  
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           Expected cost 
     Complication(s) R 4 035.27  R 72 312.04 
     (0.64) 
  Type I 
  (0.28) 
     No complication R 1 385.22  R 13 963.02 
     (0.36)  
 
Diabetes  
mellitus  
          
     Complication(s) R 3 292.05  R 175 379.50 
     (0.82)  
         
  Type II      
  (0.72)        
No complication R 1 203.45   R 14 134.95 
(0.18) 
  
 Total cost:   R 275 789.51 
 
Figure 3  Decision tree with costs 
 
Table 33 indicates the probability of certain diabetes mellitus complications occurring in 
either type I or type II diabetic patients. This data was obtained from the sample of 100 
patients using the combined method. 
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Table 33  Probabilities of complications 
 Probability of complication occurring 
Complication Type I diabetes mellitus Type II diabetes mellitus 
Neuropathy 0.56 0.64 
Nephropathy 0.56 0.59 
Retinopathy 0.39 0.34 
Ischaemic heart disease (IHD) 0.11 0.32 
Peripheral vascular disease 
(PVD) 
No data 0.08 
Acute metabolic  0.17 0.02 
 
The probabilities presented in Table 33 were not used in the cost analysis due to the small 
sample size and the fact that cost estimates for the various complications could not be 
obtained. The probabilities of these complications occurring can be used in future studies if 
cost estimates for the various complications are obtained. 
5.5.2 Model of potential costs incurred at other health facilities  
The method which was developed for a model which could predict additional costs incurred 
at other health facilities such as community health centres. Patients will visit Groote Schuur 
hospital intermittently for specialised care and management of their conditions. This model 
assumed that patients would visit community health centres to collect medicines and for 
doctor consultations. 
A sample of 10 patients was used to test the functionality of the model. The results of this 
model are summarised in Tables 34 and 35. This model utilised actual patient data obtained 
in the study using the combined method. Patients were divided into two categories i.e., 
unstable and stable patients, and the simulation was conducted for 5 patients for each 
category. This model is based on actual events that occurred at Groote Schuur hospital and 
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simulated events that could have occurred at community health centres during the study 
period.  
Table 34  Simulated costs for unstable patients 
Simulated cost for unstable patients 
Category Time 
in 
study, 
months 
Consults 
@ GSH1 
Medicine 
collection
@ GSH2 
CHC simulated events and cost Cost @ 
GSH8 
Total 
cost9 
Cost per 
12 
months10 
Consults3 Medicine 
collections4 
Consults 
cost5 
Medicine 
cost6 
Simulated 
cost total7 
Patient 1 19 3 9 10 10 R1050- 
R1410 
R4630 R5680- 
R6040 
R8821 R14501- 
R14861 
R9135- 
R9362 
Patient 2 15 2 4 11 11 R1155-  
R1551 
R600 R1755- 
R2151 
R1685 R3441- 
R3837 
R2752- 
R3069 
Patient 3 17 3 8 9 9 R945- 
R1269 
R1917 R2862- 
R2986 
R3162 R6025- 
R6149 
R4278- 
R4366 
Patient 4 18 3 3 15 15 R1575- 
R2115 
R2937 R4512- 
R5052 
R2893 R7405- 
R7945 
R4961- 
R5323 
Patient 5 18 3 4 14 14 R1470- 
R1974 
R3256 R4726- 
R5230 
R2502 R7229- 
R7733 
R4843- 
R5181 
1 Number of specialist consultations at Groote Schuur hospital during the study period. 
2 Number of medicine collections at Groote Schuur hospital during the study period. 
3 Number of consultations at the community health centre which would be conducted during the study period based on the model and actual 
consultations at GSH. 
4 Number of medicine collections at the community health centre during the study period based on actual medicine collections at GSH. 
5 Cost for consultation with nurse and doctor presented as a range and includes the cost of a blood glucose test. 
6 Total medicine cost at the community health centre including the dispensing fee based on the average cost per prescription and the number 
of medicine collections at the community health centre. 
7 Total simulated cost for consultations and medicine at the community health centre. 
8 Actual cost at GSH for study period. 
9 Total cost for the study period, includes the community health centre and GSH cost. 
10Total cost converted to a cost per year. 
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Table 35  Simulated costs for stable patients 
 
 
Simulated cost for unstable patients 
Category Time 
in 
study, 
months 
Consults 
@ GSH1 
Medicine 
collection 
@ GSH2 
CHC simulated events and cost Cost @ 
GSH8 
Total 
cost9 
Cost 
per 12 
months
10 
Consults3 Medicine 
collections4 
Consults 
cost5 
Medicine 
cost6 
Simulated 
cost total7 
Patient 6 17 2 3 4 14 R420-  
R564 
R2547 R2967- 
R3111 
R2883 R5851- 
R5995 
R4154- 
R3733 
Patient 7 18 3 4 4 14 R420-  
R564 
R2594 R3014- 
R3158 
R3970 R6984- 
R7128 
R4679- 
R4775 
Patient 8 12 2 1 3 11 R315- 
R423 
R395 R710- 
R818 
R682 R1392- 
R1500 
R1392- 
R1500 
Patient 9 20 3 9 4 13 R420-  
R564 
R2359 R2779- 
R2923 
R9771 R12551- 
R12695 
R7530- 
R7617 
Patient 
10 
19 3 6 4 13 R420-  
R564 
R3766 R4186- 
R4330 
R3038 R7224- 
R7368 
R4551- 
R4642 
1 Number of specialist consultations at Groote Schuur hospital during the study period. 
2 Number of medicine collections at Groote Schuur hospital during the study period. 
3 Number of consultations at the community health centre which would be conducted during the study period based on the model and actual 
consultations at GSH. 
4 Number of medicine collections at the community health centre during the study period based on actual medicine collections at GSH. 
5 Cost for consultation with nurse and doctor presented as a range and includes the cost of a blood glucose test. 
6 Total medicine cost at the community health centre including the dispensing fee based on the average cost per prescription and the number 
of medicine collections at the community health centre. 
7 Total simulated cost for consultations and medicine at the community health centre. 
8 Actual cost at GSH for study period. 
9 Total cost for the study period, includes the community health centre and GSH cost. 
10Total cost converted to a cost per year. 
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5.6 Total cost of diabetes mellitus and its complications  
Table 36  Total cost of diabetes mellitus and its complications at GSH 
Cost component Number of 
items 
Number of 
patients utilising 
resource 
Total cost 
(% to total cost) 
Cost per patient 
20 month period 
Consultations 4811 1094 R 1 159 451.00 
(26.8%) 
R 1 059.83 
Pharmaceutical 
supplies 
45701 893 R 1 003 101.94 
(23.2%) 
R 1 123.29 
Laboratory tests 22536 1090 R 703 190.13 
(16.3%) 
R 645.13 
Electrocardiogram 
procedures 
91 61 R 17 189.00 
(0.4%) 
R 281.95 
Radiological 
procedures 
111 75 R 16 761.00 
(0.4%) 
R 223.48 
Emergency room 
visits 
66 42 R 26 400.00 
(0.6%) 
R 628.57 
Hospitalisations 301 200 R 990 275.00 
(22.9%) 
R 4 951.38 
Surgery 91 71 R 406 446.00 
(9.4%) 
R 5 724.59 
     
Total   R 4 322 814.07 R 3 951.38 
 
Table 36 indicates the total cost for diabetes mellitus and its complications for the sample of 
1094 in the electronic database. The results obtained from the combined and electronic 
methods using 100 patients were reported based on the cost template which was developed 
(Table 21 and 23). For these methods the data were arranged in the cost template at patient 
level which allowed for calculation of costs at individual patient level. However, when using 
the sample of 1094 (Table 36), the electronic database of Groote Schuur hospital was used as 
presented without using the cost template to arrange data at patient level. In this case, the data 
were presented at cost component level in various databases.  
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Hospitalisation data was presented in two databases i.e., one database had information on the 
admission date and reason for hospitalisation and the other database had information on the 
discharge date and length of stay. Hence, in this evaluation only the total costs for all the cost 
components were determined.  
The database as it was presented by Medical Informatics did not allow for re-arrangement of 
data at patient level. The information was not available at individual patient level, hence, the 
cost per patient is reported and not the average cost per patient with the application of 
descriptive statistics. The cost per patient was found to be R 3 951.38 and was calculated by 
dividing the cost per component by the number of patients utilising that particular 
component. This approach could be used to determine the cost of diabetes mellitus and its 
complications at cost component level using the database in its current form.  
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CHAPTER 6 
DISCUSSION  
There is no documented data in South Africa on the cost of treating diabetes mellitus and its 
complications at a tertiary level hospital. This study was conducted to address this issue. This 
retrospective study was conducted primarily to: (1) develop a method which is unique to 
Groote Schuur hospital for determining the cost of management of diabetes mellitus and its 
complications, (2) quantify the direct medical costs associated with the management of 
diabetes mellitus and its complications and (3) develop models which could predict the cost 
of management of diabetes mellitus and its complications. This study was conducted from the 
perspective of the funder i.e., the government. 
Our study found that 28% of the patients were type I diabetics; this is higher than literature 
findings of 5 – 10% (Deshpande et al. 2008). An explanation is that Groote Schuur hospital is 
a tertiary level facility and therefore it is not uncommon for more patients with type I diabetes 
mellitus to be treated at this facility. The majority of the patients had diabetes mellitus related 
complications (77%) and certain co-morbid conditions are risk factors for the development of 
these complications. According to a UKPDS study (Clarke et al. 2003) conditions such as 
hypertension and dyslipidaemia are risk factors for various complications of diabetes 
mellitus. These co-morbid conditions were also the highest ranking co-morbid conditions in 
our study. The most commonly occurring complication of diabetes mellitus in our study was 
neuropathy (48%), this is in line with what has been found in literature, viz. that 50 – 60% of 
diabetic patients suffer from neuropathy (Zhao et al. 2010). 
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6.1 Development of the costing method 
The primary focus of our study was to develop a method to quantify the cost associated with 
the treatment of diabetes mellitus and its complications. This method was unique to Groote 
Schuur hospital and was based on the data sources which were available. Two distinct 
methods were developed i.e. combined method (patient folders and electronic patient records) 
and electronic method (electronic patient records). Patients were selected from the electronic 
database based on their attendance to the adult diabetic clinic. This was the preferred method 
of extraction in our study as opposed to the conventional method of using IDC-10 codes as 
used in most cost studies (Ramsey et al. 1999, Gandra et al. 2006, Clarke et al. 2008). The 
accuracy of recording ICD-10 codes in the electronic database of patient records was reported 
to be 70 % by the Medical Informatics department at Groote Schuur hospital. The method 
used in our study indicated that 99.1% of the patients extracted were diabetic. Therefore, our 
method can therefore be useful for extracting patients when ICD-10 codes are not available. 
The combined method provided advantages such as primary diagnosis and other patient co-
morbidities. This information is important when the costs are separated into costs due to 
diabetes mellitus or complications of diabetes mellitus. A further advantage of this method is 
that the reasons for every hospital and emergency room visit will be known, this is important 
as hospitalisation is a large contributor to the total cost of treatment. The electronic method is 
not able to categorise costs as the combined method which is a disadvantage. Hence, the 
electronic method can only report the total cost for diabetes mellitus and its complications. 
This information can be useful when assessing the overall financial impact that diabetes 
mellitus and its complications had on the total expenditure of the hospital. Using a method 
which is able to categorise costs such as the combined method is more useful as the funder is 
able to determine the percentage of the total cost being used to treat the complications of 
diabetes mellitus and therefore impact decisions which affect allocation of monetary 
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resources. These two methods were compared with regards to the total cost obtained and the 
electronic method obtained costs which were 6.4% higher than the combined method. The 
cost differences between these two methods were not statistically significant. Therefore, the 
electronic method can be used as it is similar to using the combined method.  
A study by Morsanutto et al. (2006) combined two data sources i.e., patient folders and 
electronic patient records. This study was conducted from the perspective of the funder and 
costs were derived from the Italian health ministry reference price list. The health care 
facility was a diabetes specific facility.  This study did not assess what value the patient 
folders added to the cost of illness study. The study by Riewpaiboon et al. (2007) utilised 
patient folders as the only data source and was conducted from the perspective of the funder 
of treatment in a primary health care facility. Our study is able to assess the impact which the 
patient folders has on the categorisation of costs and the difference in the total costs obtained 
when using two different methods of costing. 
Studies which have been conducted in developed countries utilised large databases from 
managed health care organisations (Pelletier et al. 2008; Gandra et al. 2006; Clarke et al. 
2006). The costs presented in these studies represent the cost to the managed health care 
organisation, whereas our study presented costs from the perspective of the government. The 
perspective of our study and those studies mentioned above are the same, but for the funder 
of the treatment. The advantage of using an electronic database is the large sample size which 
is obtained. The electronic method which was developed in our study can provide a larger 
sample of patients, but the database in its current form will have to be changed (as will be 
recommended in Chapter 7) in order to provide this advantage to future researchers.  
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6.2 Cost of diabetes mellitus and its complications 
The cost data which are presented in various studies including our study are influenced by a 
number of factors. Studies conducted in some European countries (Morsanutto et al. 2006; 
Massi-Benedetti. 2002) have the advantage of a national reference price list, which is not 
available in South Africa. Our study used prices from the UPFS Provincial Gazette for 
Western Cape No. 6862, 25 March 2011, these being the prices that were used by the hospital 
to bill patients who are privately funded. However, these prices do not represent what it costs 
the hospital to provide its patients with specific health care services. This is currently the only 
source of costs available in the public sector. This did pose a particular challenge for this 
study as one of the main objectives was to cost diabetes mellitus and its complications from 
the perspective of the government. Therefore, using prices charged to private patients would 
not fully achieve this objective although the prices obtained in the UPFS fee schedule are 
conservative. The UPFS fee was developed by the National Department of Health (NDoH) of 
South Africa. The NDoH was contacted to enquire about the method of calculating this fee 
schedule. This information would then have been used to determine whether a profit margin 
was incorporated into the fee schedule and we would be able to determine what the true cost 
was for providing the services outlined in the UPFS fee schedule. The NDoH was unable to 
provide the information requested as they had used no specific method to determine these 
prices. The fees in the UPFS were merely estimated in 2004 and thereafter inflation adjusted 
for each year. This is another area in which South Africa lacks information which would be 
greatly beneficial to health care decision makers, particularly taking account the 
implementation of the NHI. 
In order to obtain the actual cost for providing services at Groote Schuur hospital, a 
comprehensive cost study will have to be undertaken based on the financial statements, time 
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motion studies and determining the cost per bed and facility. This falls outside the scope of 
this study. For the purpose of this study, we have explored what is needed for a 
comprehensive cost study to be conducted. 
Time motion studies would provide a cost for each of the above health care services. This 
cost is obtained per time spent conducting these services. These studies provide an average 
time spent per patient (for doctor and nurse time) that can then be multiplied by the hourly 
rate of the health care provider conducting the consultation from which a final cost can be 
obtained. The pharmacy personnel cost is calculated by determining the average time it takes 
to dispense a diabetes mellitus related prescription. The time unit is then multiplied by the 
hourly rate for the pharmacy staff involved in dispensing the prescription.  
A national reference price list would enable results obtained in the same country to be 
compared if the same sources of costs are used. This would enable the collection of cost data 
in that particular country that could be used by government and other funders. 
The perspective of the study is important as this is an indicator of which costs will be 
assessed. Our study assessed the direct medical costs associated with diabetes mellitus and its 
complications. Many diabetes mellitus cost studies assessed the direct medical costs (Pelletier 
et al. 2008; Gandra et al. 2006; Clarke et al. 2006) which were the same as our study. These 
studies were conducted from the perspective of the managed health care organisations. Our 
study’s perspective is that of a government which reports acquisition costs which are 
different to the costs reported in the studies mentioned above.  
The studies by Morsanutto et al. (2006); Massi-Benedetti. (2002) and Riewpaiboon et al. 
(2007) report acquisition costs which is similar to our study. Although these results cannot be 
compared to our study due to differences in source of costs, currency differences and health 
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care system differences, we are able to compare the impact of various cost components on the 
total cost and draw some conclusions and similarities.  
In our study the cost of treating diabetes mellitus and its complications was R 2 744.80 per 
patient per year (Table 17, page 59). Patient grouping had an impact on the cost, the cost of 
treating a patient with diabetes mellitus only (n=23) was R 1 231.54 per year (Table 24, page 
68). Treating a patient with diabetes mellitus and complication (s) (n=77) was R 3 208.71 per 
year (Table 24, page 67). This showed the importance of categorising costs and reporting 
costs based on whether the patient had a diabetes mellitus complication or not.  
Our study showed that the cost of treating the complications of diabetes mellitus is more than 
diabetes mellitus with 60.7% (Table 17, page 59) of the total cost being attributable to the 
complications of diabetes mellitus. Studies by Norlund et al (2001) and Williams et al (2002) 
found that 50% of the total treatment cost was due to the complications of diabetes mellitus.  
Our study indicated that diabetes mellitus with complications cost 2.6 times more to treat 
than diabetes mellitus without complications. There have been studies which support this 
finding. Pelletier et al (2009) and Massi-Benedetti (2002) assessed microvascular 
complications of diabetes mellitus in type II diabetics and found that the costs were increased 
2-fold versus diabetic patients without any complications.  
6.2.1 Cost of various components  
The cost components described in our study have different impacts on the cost of diabetes 
mellitus and its complications. Our study found that hospitalisation was the major cost driver, 
contributing 23.8% of the total cost (Table 18, page 60).  Morsanutto et al. 2006 found 
similar results in that hospitalisations contributed 28 % of the total cost. Dawson et al. (2000) 
found that 50 % of the cost was due to hospitalisations. Jonsson B. (2002) reported that as 
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much as 65 % of the total cost was due to hospitalisations. While all these results indicate that 
hospitalisation is a major cost driver, the variation may be due to different methods used in 
costing the hospital event and the different cost components included in the final hospital 
cost. 
In our study only 13 % of the patients were hospitalised, at an average cost of R 8 360.00 per 
patient (Table 21, page 63). This was 1.8 times more than the average cost per patient to treat 
diabetes mellitus. This further emphasised the financial impact of hospital care on the cost of 
treating the complications of diabetes mellitus. 
Health care resources such as doctor consultations, pharmacy supplies and laboratory tests 
had a substantial impact on the total cost but this is to be expected as almost all the patients 
(98%) utilised these. Our study found consultations, pharmacy supplies and laboratory tests 
to be 22.2%, 21.4% and 19.2%, respectively, of the total cost. Dawson et al. (2000) reported 
doctor consultations and medicines as 31% and 19%, respectively, of the total cost. 
Morsanutto et al. (2006) reported doctor consults, medicine and laboratory tests as 6%, 52% 
and 11%, respectively, of the total cost. The results reported by Dawson et al. (2000), showed 
that only the doctor consultations were comparable to our study.  
In the study of Morsanutto et al. (2006) medicine cost was taken from the Italian official 
market reference price list which represented market prices. This was different to our study in 
that medicine cost was taken from state tender prices (representing acquisition costs) and 
these tender prices are lower than the market prices (single exit price (SEP) as it is referred to 
in South Africa). In the study of Morsanutto et al. (2006) medicine cost was 52% of the total 
cost and this could be a contributing factor. The source of costs impacts the conclusions 
which can be made from the various studies and therefore it is important that this factor is 
taken into account when comparing cost studies.  
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Our study reported the acquisition cost for medicines and the study by Riewpaiboon et al. 
(2007) was same in this respect. Riewpaiboon et al. (2007) reported that medicines were     
45 % of the total cost. This difference with our study is that vitamins were included in the 
cost of medicines and the acquisition cost for various medicines does vary in Thailand as 
reported by the researchers. The study was conducted in a primary health care facility and it 
was expected that medicine costs would be the greatest contributor to the total cost as patients 
visited this facility monthly to collect medicines. This was further highlighted by the finding 
that the outpatient cost in that study was found to be 1.5 times more than the inpatient cost. 
This was not the case with Groote Schuur hospital, as patients receive specialised care and 
would collect their monthly medicines at the primary health care facilities. 
6.2.2 Categorisation of costs 
Our study was able to categorise costs into either (1) costs due to diabetes mellitus or (2) 
costs due to the complications of diabetes mellitus. This categorisation was possible when the 
combined method was used. Our study found that the patient folders added value to the 
overall cost estimates. The patient folders provided valuable information such as the type of 
diabetes mellitus and the type of diabetes mellitus complications. This information is 
important as it allows for costs to be categorised. The patient folders were of value when 
completing missing information in the electronic database, particularly the reasons for 
emergency room visits and hospitalisations. Hospitalisations can greatly affect the cost. 
Hence, the reasons for these events should be accurately recorded and incomplete 
information can lead to under- or over-estimation of the hospital cost. None of the other 
studies was able to distinctly categorise costs as effectively as has been accomplished in our 
study. Our study further identified the various sub-components which were included in the 
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cost components i.e., hospitalisation cost which consisted of the cost per day, laboratory tests, 
electrocardiogram and radiological procedures conducted during the hospital event. 
6.3 Predictive cost models 
Models which use probabilities of events occurring are more commonly found in literature. 
Clarke et al (2008); Riewpaiboon et al (2007) and O’Brien et al (2003) developed models 
which can predict costs. The study by Clarke et al (2008) used estimates of the occurrence of 
diabetes mellitus complications to predict the cost of these events using costs obtained from 
the national reference prices. The decision tree model which we developed used a different 
approach with regard to obtaining probabilities of diabetes mellitus complications occurring 
as our study obtained the probabilities for various categories and the cost estimates for these 
using the data obtained at Groote Schuur hospital. This model (as shown in the Chapter 5) is 
able to predict costs in the Groote Schuur hospital diabetic population and it was found that 
the cost results obtained varied by only 0.23% from the actual cost. These cost estimates and 
probabilities were obtained using a sample of 100 patients.  
Our study demonstrated that a method for a model could be developed which took into 
account potential costs which the study population would incur at community health centres. 
To obtain total costs including those incurred at primary health care facilities, a simulated 
cost model could be used. 
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6.4 Limitations of the study 
The study had the following limitations: 
a) The sample size of 100 was small and as a result cost estimates for the individual 
complications of diabetes mellitus was not possible. 
b) Data for 20 months only was collected as this was what was available at the time of 
data collection. Data should be collected for an extended period of time. This would 
allow for costs to be analysed over time as complications progress. 
c) The use of UPFS Provincial Gazette for Western Cape No. 6862, 25 March 2011, fee 
schedule as acquisition costs for Groote Schuur hospital were not available. 
d) The high number of patient folders which were missing from the Medical Records 
department at Groote Schuur hospital limited the sample size of the patients for this 
study. 
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
This study was the first of its kind in a tertiary level hospital in South Africa. The methods 
developed in this study can be used and validated in future research. This study successfully 
achieved its objectives and provided cost estimates for diabetes mellitus and its complications 
which can be used in future research and assist in the financial decision making process of 
funders such as the government.  
7.1 Conclusions 
The following conclusions were drawn from this study: 
a) Four unique methods were developed to determine the cost of management of 
diabetes mellitus and its complications at Groote Schuur hospital (combined, 
electronic, decision tree and CHC cost model). Although these methods have been 
specifically designed for Groote Schuur hospital, there is no reason why these 
methods cannot be applied to other public tertiary level hospitals which have patient 
folders, and an electronic database of patient records. 
b)  The two main methods developed were the combined and electronic method. The 
electronic method estimated a total cost which was 6.4% more than the combined 
method. However, there was no statistically significant difference between the two 
methods. The electronic database method provides the total and average cost per 
patient. The costs associated with sub-groups such as type I and type II diabetic 
patients could not be determined using this method. Despite this, the electronic 
method does not require the perusal of patient folders for additional information and 
hence is a simplified method. 
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c) The combined method allowed better categorisation of costs compared to the 
electronic method. With the combined method the type of diabetes mellitus 
complication, the reasons for emergency room visits and hospitalisations are known. 
Therefore, costs associated with diabetes mellitus (type I or type II) and diabetes 
mellitus complications could be categorised.   
d) The average cost per patient per year for diabetes mellitus and diabetes mellitus with 
complications was R 1 231.54 and R 3 208.71, respectively. These results show that a 
patient with diabetes mellitus and its complications cost 2.6 times more to treat than a 
patient with diabetes mellitus only. 
e) When cost of treating diabetes mellitus and the cost of treating the complications of 
diabetes mellitus were separated into 2 distinct categories, the cost of treating the 
complications of diabetes mellitus was 1.5 times more than treating diabetes mellitus.   
f) When evaluating the cost per patient for the various cost components, then 
hospitalisation and surgery costs were the main cost drivers on a per patient basis.   
g) Type I diabetes mellitus cost R 3 011.32 and type II diabetes mellitus cost R 2 649.40 
per patient per year. The type of diabetes mellitus had an impact on the average cost 
of treatment. The treatment costs for type I diabetic patients was 13.7% more than that 
for type II diabetic patients. 
h) The decision tree model obtained a cost result which was 0.23% more than the actual 
cost. This indicates that this model can therefore be applied to predict costs at Groote 
Schuur hospital. 
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i) The study developed a method which could be used to predict the cost of management 
of diabetes mellitus at community health centres. This will allow the calculation of the 
total cost of diabetes mellitus from the perspective of the government. 
7.2 Recommendations 
a) In future research the methods and models developed in this study can be used at 
other tertiary level facilities to provide costs for diabetes mellitus and its 
complications. These methods developed in this study can be validated for 
reproducibility in other public tertiary level hospitals in South Africa. 
b) In order to conduct future cost studies at Groote Schuur hospital in the future which 
will allow for categorisation of costs, i.e., diabetes mellitus and the complications of 
diabetes mellitus, the combined method should be used. 
c) If, in the future, cost studies are conducted at Groote Schuur hospital the electronic 
method could be used to obtain average and total costs of diabetes mellitus and its 
complications. The electronic database at Groote Schuur hospital should be upgraded 
in order to improve the capturing of clinical information such as the patient diagnosis 
and co-morbid conditions. The reasons for hospitalisation and emergency room visits 
should be provided for each patient and incorporated into the database. This will 
allow for the categorisation of costs. More consistent and accurate ICD-10 codes will 
make it easier for patients to be selected for inclusion into cost studies. 
d) Medicine costs could not be extracted from the electronic database as these costs were 
incorrect. These costs should be extracted directly from the pharmacy department at 
Groote Schuur hospital. 
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e) The decision tree model should be developed further by obtaining cost estimates and 
probabilities of the individual complications occurring from a larger sample size. 
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Annexure 1  Diabetes clinic doctor form 
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Annexure 2 Statistical analysis 
Diabetes mellitus versus diabetes mellitus with complications 
 
Analysis of Variance Report  
Response Total Cost 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 9.26 0.00 Reject 
Kurtosis Normality of Residuals 6.82 0.00 Reject 
Omnibus Normality of Residuals 132.49 0.00 Reject 
Modified-Levene Equal-Variance Test 2.12 0.14 Accept 
 
Box Plot Section 
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Box Plot 
Variables 
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Diabetes mellitus versus diabetes mellitus with complications 
 
Analysis of Variance Report  
Response Total Cost 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level Decision(0.05) 
Not Corrected for Ties 1 14.41 0.000147 Reject Ho 
Corrected for Ties 1 14.41 0.000147 Reject Ho 
 
Number Sets of Ties 0 
Multiplicity Factor 0 
 
Group Detail 
  Sum of Average 
Group Count Ranks Rank Z-Value Median 
Complications 77 4352.00 56.52 3.79 3038.08 
No complications 23 698.00 30.35 -3.79 1800.79 
 
Means and Effects Section 
   Standard  
Term Count Average Error Effect 
All 100 4574.67 73.80 
Complications 77 5328.03 778.38 5254.22 
No complications 23 2052.56 1424.22 1978.75 
 
 
Tukey-Kramer Multiple-Comparison Test 
 
Response: Total Cost 
 
Alpha=0.05  Error Term=S(A)  DF=98  MSE=4.66E+07 Critical Value=2.80 
 
    
Group Count Average 
No complications 23 2052.56  
Complications 77 5328.03 
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between the means. 
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Diabetes mellitus versus diabetes mellitus with complications 
 
Analysis of Variance Report (ANOVA) 
Response Total Cost 
 
 
Kruskal-Wallis Multiple-Comparison Z-Value Test 
 
Total Cost Complications  No complications 
Complications 0.00  3.79 
No complications 3.79  0.00 
 
Regular Test: Medians significantly different if z-value > 1.96 
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Type I versus Type II diabetes mellitus 
 
Analysis of Variance Report  
Response Total Cost 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 9.26 0.00 Reject 
Kurtosis Normality of Residuals 6.81 0.00 Reject 
Omnibus Normality of Residuals 132.32 0.00 Reject 
Modified-Levene Equal-Variance Test 0.32 0.56 Accept 
 
Box Plot Section 
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Type I versus Type II diabetes mellitus 
 
Analysis of Variance Report (ANOVA) 
  
Response Total Cost 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level Decision(0.05) 
Not Corrected for Ties 1 7.21E-02 0.788 Accept Ho 
Corrected for Ties 1 7.21E-02 0.788 Accept Ho 
 
Number Sets of Ties 0 
Multiplicity Factor 0 
 
Group Detail 
  Sum of Average 
Group Count Ranks Rank Z-Value Median 
Type I 28 1379.00 49.25 -0.2687 2938.42 
Type II 72 3671.00 50.99 0.2687 2836.42 
 
Means and Effects Section 
   Standard  
Term Count Average Error Effect 
Type I 28 4990.29 1316 4896.26 
Type II 72 4413.04 820.94 4319.00 
 
 
Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: Total Cost 
Term A: Type 
 
Alpha=0.05  Error Term=S(A)  DF=98  MSE=4.85E+07 Critical Value=1.98 
 
    
Group Count Average 
Type II 72 4413.04  
Type I 28 4990.29  
 
Notes:  
This section presents the results of all paired comparisons among the means. 
Since this procedure uses the Bonferroni inequality, it is not as accurate as the Tukey-Kramer's method. 
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Type I versus Type II diabetes mellitus 
 
Analysis of Variance Report (ANOVA) 
Response Total Cost 
 
 
Tukey-Kramer Multiple-Comparison Test 
 
Response: Total Cost 
 
Alpha=0.05  Error Term=S(A)  DF=98  MSE=4.85E+07 Critical Value=2.80 
 
    
Group Count Average 
Type II 72 4413.04  
Type I 28 4990.29  
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between the means. 
 
 
 
Kruskal-Wallis Multiple-Comparison Z-Value Test 
 
Total Cost Type I Type II 
Type I 0.00 0.27 
Type II 0.27 0.00 
Regular Test: Medians significantly different if z-value > 1.96 
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Annexure 3 Fields within Cost Template 
Cost Template Fields 
Demographics 
Patient hospital identification number 
Gender 
Date of birth 
Type of diabetes mellitus 
Complications of diabetes mellitus 
Co-morbid conditions 
Emergency room visits 
Date of emergency room visit 
Reason for emergency room visit (if 
available) 
Cost of laboratory tests, electrocardiogram 
and radiological procedures 
Total cost 
Outpatient consultations 
Date of consultation 
Reason for consultation (if available) 
Cost of consultation 
Hospitalisations  
Date of hospitalisation 
Length of stay (in days) 
Reason for hospitalisation (if available) 
Cost of laboratory tests, electrocardiogram 
and radiological procedures 
Total cost 
 
Radiological procedures 
Date of procedure 
Type of procedure 
Cost of procedure 
Medicines 
Date of dispensing 
Name of medicine 
Quantity and strength dispensed 
Cost of medicine 
Cost of dispensing 
 
Electrocardiogram procedures 
Date of procedure 
Type of procedure 
Cost of procedure 
Laboratory tests 
Date of test 
Type of test 
Cost of test 
 
 
 
 
 
